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Abstract
The United Arab Emirates (UAE) has experienced a rapid economic growth that was
paralleled with a drastic rise in non-communicable diseases (NCDs); primarily
cardiovascular diseases (CVDs), which account for 40% of mortality in UAE. CVDs
have complex etiology, interplay and accumulation of many risk factors.
Understanding the clustering and interrelationships between common risk factors like
obesity, dysglycemia, dyslipidemia, hypertension and central obesity, and the
associations with social and lifestyle determinants, is warranted. The study aimed to
estimate the burden of cardiometabolic risk factors (CRFs), their interrelationship, and
their associations with other social and lifestyle determinants in a young Emirati
population. Data was drawn from the UAE Healthy Future Study collected between
2016 and 2018. The information was collected through questionnaires, physical
measurements and blood samples. Age-adjusted and gender-specific prevalence of
CRFs were estimated, and appropriate regression models were used to determine the
interrelationships and associations of the CRFs. A total of 5,167 eligible participants
aged 18-40 were included in the analysis. The age-adjusted prevalence rates were
26.5% for obesity, 11.7% for dysglycemia, 62.7% for dyslipidemia, 22.4% for
hypertension and 22.5% for central obesity. Dyslipidemia had the highest comorbidity
rate, up to 80%, with other CRFs, followed by obesity. Obesity had the strongest
interrelationship with other CRFs. Education, employment, smoking and family
history of NCDs had significant associations with some CRFs. Forty percent of the
population had ≥2 CRFs, and the accumulation was higher in men than women; 47.8%
vs 28.1%, respectively. The burden of CRFs was affected by age and social factors,
and was significantly different across BMI classes. CRFs and their clustering are
highly prevalent in young adults, including those of normal BMI. This should be taken
into account in the design and targeting of group-specific measures for CVDs and other
NCDs prevention. Further research is needed to investigate how the clustering
manifests in young adults to prevent the early rise of NCDs in the UAE.
Keywords: Non-communicable disease, Cardiovascular disease, Cardiometabolic risk
factors, Obesity, Dysglycemia, Dyslipidemia, Hypertension, Central obesity.
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)Title and Abstract (in Arabic

اﻧﺘﺸﺎر وﻋﺐء ﻋﻮاﻣﻞ ﻣﺨﺎطﺮ اﻹﺻﺎﺑﺔ ﺑﺎﻷﻣﺮاض اﻟﻘﻠﺒﯿﺔ ﻋﻨﺪ اﻹﻣﺎراﺗﯿﯿﻦ اﻟﺸﺒﺎب
اﻟﻤﻠﺨﺺ

ﺷﮭﺪت دوﻟﺔ اﻹﻣﺎرات ﻧﻤﻮا ً ﺳﺮﯾﻌﺎ ً ﻓﻲ اﻻﻗﺘﺼﺎد ،وواﻛﺐ ھﺬا اﻟﻨﻤﻮ ارﺗﻔﺎع ﺣﺎد ﻓﻲ اﻷﻣﺮاض ﻏﯿﺮ
اﻟﻤﻌﺪﯾﺔ؛ ﺣﯿﺚ ﺗﻌﺪ أﻣﺮاض اﻟﻘﻠﺐ واﻷوﻋﯿﺔ اﻟﺪﻣﻮﯾﺔ ﻓﻲ اﻟﻤﻘﺎم اﻷول ،واﻟﺘﻲ ﺗﻤﺜﻞ  %40ﻣﻦ أﺳﺒﺎب
اﻟﻮﻓﯿﺎت ﻓﻲ دوﻟﺔ اﻹﻣﺎرات اﻟﻌﺮﺑﯿﺔ اﻟﻤﺘﺤﺪة .وﻋﻼوة ﻋﻠﻰ ذﻟﻚ ،ﻓﺈن ھﺬه اﻷﻣﺮاض اﻟﻘﻠﺒﯿﺔ اﻟﻮﻋﺎﺋﯿﺔ
ﻟﮭﺎ ﻣﺴﺒﺒﺎت ﻣﺘﻌﺪدة اﻟﻌﻮاﻣﻞ وﻣﻌﻘﺪة .ﻟﺬﻟﻚ ﯾﺘﻮﺟﺐ ﻋﻠﯿﻨﺎ ﻓﮭﻢ اﻟﺘﻜﺘﻞ واﻟﻌﻼﻗﺎت اﻟﻤﺘﺒﺎدﻟﺔ ﺑﯿﻦ ﻋﻮاﻣﻞ
اﻟﺨﻄﺮ اﻟﻤﻨﺘﺸﺮة ﻣﺜﻞ اﻟﺴﻤﻨﺔ وﺳﻜﺮ اﻟﺪم وارﺗﻔﺎع ﻧﺴﺒﺔ اﻟﺪھﻮن ﻓﺎﻟﺪم وارﺗﻔﺎع ﺿﻐﻂ اﻟﺪم واﻟﺴﻤﻨﺔ
اﻟﻤﺮﻛﺰﯾﺔ ،وﻣﻦ اﻟﻤﮭﻢ ﻓﮭﻢ ارﺗﺒﺎطﮭﺎ ﺑﺎﻟﻌﻮاﻣﻞ اﻻﺟﺘﻤﺎﻋﯿﺔ اﻷﺧﺮى وﻣﺤﺪدات ﻧﻤﻂ اﻟﺤﯿﺎة .ھﺪﻓﺖ
ھﺬه اﻟﺪراﺳﺔ إﻟﻰ ﺗﻘﺪﯾﺮ ﻋﺐء ﻋﻮاﻣﻞ اﻟﺨﻄﺮ اﻟﻘﻠﺒﯿﺔ واﻟﺘﺤﻘﯿﻖ ﻓﻲ ﺗﺮاﺑﻄﮭﺎ ﻣﻊ ﺑﻌﻀﮭﺎ اﻟﺒﻌﺾ،
وارﺗﺒﺎطﮭﺎ ﺑﺎﻟﻌﻮاﻣﻞ اﻻﺟﺘﻤﺎﻋﯿﺔ وﻣﺤﺪدات ﻧﻤﻂ اﻟﺤﯿﺎة اﻷﺧﺮى ﻓﻲ اﻹﻣﺎراﺗﯿﯿﻦ اﻟﺸﺒﺎب .ﺗﻢ
اﺳﺘﺨﻼص اﻟﺒﯿﺎﻧﺎت ﻣﻦ دراﺳﺔ "ﻣﺴﺘﻘﺒﻞ ﺻﺤﻲ ﻟﻺﻣﺎرات" اﻟﺘﻲ ﺗﻢ ﺟﻤﻌﮭﺎ ﺑﯿﻦ ﻋﺎﻣﻲ 2016
و ،2018ﺣﯿﺚ ﺗﻢ ﺟﻤﻊ اﻟﻤﻌﻠﻮﻣﺎت ﻣﻦ ﺧﻼل اﺳﺘﺒﯿﺎﻧﺎت وﻗﯿﺎﺳﺎت ﺑﺪﻧﯿﺔ وﻋﯿﻨﺎت اﻟﺪم .ﻗُ ِﺪّر ﻋﺐء
ﻋﻮاﻣﻞ اﻟﺨﻄﺮ ﻟﻜﻞ ﻓﺮد ،وﻗُ ِﺪّر ﻣﻌﺪل اﻧﺘﺸﺎر ھﺬه اﻟﻤﻌﺪﻻت ﺣﺴﺐ اﻟﻌﻤﺮ واﻟﺠﻨﺲ ،واﺳﺘُﺨﺪﻣﺖ
ﻧﻤﺎذج اﻻﻧﺤﺪار اﻟﻼزﻣﺔ ﻟﺘﺤﺪﯾﺪ اﻟﻌﻼﻗﺎت اﻟﻤﺘﺒﺎدﻟﺔ ﺑﯿﻦ ھﺬه اﻟﻌﻮاﻣﻞ وارﺗﺒﺎطﺎﺗﮭﺎ ﺑﺎﻟﻌﻮاﻣﻞ اﻷﺧﺮى.
ﺷﻤﻞ اﻟﺘﺤﻠﯿﻞ  5,126ﻣﺸﺎرﻛﺎ ً ﻣﻦ  18-40ﺳﻨﺔ وﻛﺎﻧﺖ ﻣﻌﺪﻻت اﻻﻧﺘﺸﺎر اﻟﻤﻌﺪﻟﺔ ﺣﺴﺐ اﻟﻌﻤﺮ
 ٪26.5ﻟﻠﺴﻤﻨﺔ ،و ٪11.7ﻟﺴﻜﺮ اﻟﺪم ٪62.7 ،ﻻرﺗﻔﺎع اﻟﺪھﻮن ﻓﺎﻟﺪم ،و %22.4ﻻرﺗﻔﺎع ﺿﻐﻂ
اﻟﺪم و ٪22.5ﻟﻠﺴﻤﻨﺔ اﻟﻤﺮﻛﺰﯾﺔ .ﻛﺎن ارﺗﻔﺎع ﻧﺴﺒﺔ اﻟﺪھﻮن ﻓﺎﻟﺪم أﻛﺜﺮ ﻋﺎﻣﻞ ﺧﻄﺮ ﺗﻮاﺟﺪ ﻣﻊ ﻏﯿﺮه
ﻣﻦ اﻟﻌﻮاﻣﻞ ﻟﺤﺪ  %80ﻣﻦ اﻟﻮﻗﺖ ،وﯾﺘﻠﻮه اﻟﺴﻤﻨﺔ اﻟﻤﻔﺮطﺔ .وﻛﺎن ﻟﻠﺴﻤﻨﺔ أﻗﻮى ﻋﻼﻗﺔ ﻣﺘﺮاﺑﻄﺔ ﻣﻊ
ﻋﻮاﻣﻞ اﻟﺨﻄﺮ اﻷﺧﺮى .أﺛﺒﺘﻨﺎ أن ﻷﺣﻮال اﻟﺘﻌﻠﯿﻢ واﻟﻌﻤﻞ واﻟﺘﺪﺧﯿﻦ واﻟﺘﺎرﯾﺦ اﻷﺳﺮي ﻟﻸﻣﺮاض
ﻏﯿﺮ اﻟﻤﻌﺪﯾﺔ ﻟﮫ رواﺑﻂ ﻛﺒﯿﺮة ﻣﻊ ﺑﻌﺾ ﻋﻮاﻣﻞ اﻟﺨﻄﺮ اﻟﻤﺬﻛﻮرة .ووﺟﺪﻧﺎ أن  %40ﻣﻦ ﺷﺮﯾﺤﺔ
اﻟﺸﺒﺎب ﯾﺮاﻛﻤﻮن أﻛﺜﺮ ﻣﻦ ﻋﺎﻣﻠﻲ ﺧﻄﺮ ﻓﻲ آن واﺣﺪ ،وﻛﺎﻧﺖ ﻧﺴﺒﺔ اﻟﺘﺮاﻛﻢ أﻋﻠﻰ ﺑﯿﻦ اﻟﺬﻛﻮر ﻋﻠﻰ
اﻹﻧﺎث  %47.8ﻣﻘﺎﺑﻞ  .%28.1ﺗﺄﺛﺮ اﻟﺘﺮاﻛﻢ ﺑﺸﻜﻞ ﻛﺒﯿﺮ ﺑﺎﻟﻌﻤﺮ واﻟﻌﻮاﻣﻞ اﻻﺟﺘﻤﺎﻋﯿﺔ .وﻛﺎن ﻋﺐء
اﻟﺘﺮاﻛﻢ ﻟﻌﻮاﻣﻞ اﻟﺨﻄﺮ ﻣﺨﺘﻠﻔﺎ ً ﺑﺸﻜﻞ ﻛﺒﯿﺮ ﻋﺒﺮ ﻓﺌﺎت ﻣﺆﺷﺮ ﻛﺘﻠﺔ اﻟﺠﺴﻢ .إن ارﺗﻔﺎع ﻋﻮاﻣﻞ اﻟﺨﻄﺮ
ﻟﻸﻣﺮاض اﻟﻘﻠﺒﯿﺔ وﺗﺮاﻛﻤﮭﺎ أﺻﺒﺢ ﺧﻄﺮا ً ﯾﮭﺪد ﺑﺸﻜﻞ ﻛﺒﯿﺮ ﻓﺌﺔ اﻟﺸﺒﺎب ﻓﻲ دوﻟﺔ اﻹﻣﺎرات اﻟﻌﺮﺑﯿﺔ
اﻟﻤﺘﺤﺪة ﺣﺘﻰ ﻣﻦ ھﻢ دون ارﺗﻔﺎع اﻟﻮزن اﻟﻤﻔﺮط .وﯾﺘﺄﺛﺮ ﻋﺐء وﺗﺠﻤﯿﻊ ﻋﻮاﻣﻞ اﻟﺨﻄﺮ ھﺬه ﺑﺎﻟﻌﻤﺮ
وﻧﻮع اﻟﺠﻨﺲ واﻟﺘﻌﻠﯿﻢ واﻟﻌﻤﺎﻟﺔ واﻟﺘﺪﺧﯿﻦ واﻟﺘﺎرﯾﺦ اﻷﺳﺮي ﻟﻸﻣﺮاض ﻏﯿﺮ اﻟﻤﻌﺪﯾﺔ .وﯾﻨﺒﻐﻲ أن
ﯾﺆﺧﺬ ذﻟﻚ ﻓﻲ ﻋﯿﻦ اﻻﻋﺘﺒﺎر ﻋﻨﺪ ﺗﺼﻤﯿﻢ واﺳﺘﮭﺪاف اﻟﺘﺪاﺑﯿﺮ اﻟﺨﺎﺻﺔ ﺑﻜﻞ ﻣﺠﻤﻮﻋﺔ ﻟﻠﻮﻗﺎﯾﺔ ﻣﻦ
اﻷﻣﺮاض اﻟﻘﻠﺒﯿﺔ اﻟﻮﻋﺎﺋﯿﺔ ﺑﺼﻔﺔ ﺧﺎﺻﺔ وﻏﯿﺮھﺎ ﻣﻦ اﻷﻣﺮاض ﻏﯿﺮ اﻟﻤﻌﺪﯾﺔ ﺑﻮﺟﮫ ﻋﺎم .وﺛﻤﺔ ﺣﺎﺟﺔ
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إﻟﻰ إﺟﺮاء ﻣﺰﯾﺪ ﻣﻦ اﻟﺒﺤﻮث ﻟﻠﺘﺤﻘﯿﻖ ﻓﻲ ﻛﯿﻔﯿﺔ ظﮭﻮرھﺎ ﺑﯿﻦ اﻟﺸﺒﺎب ﻟﻤﻨﻊ اﻟﺰﯾﺎدة اﻟﻤﺒﻜﺮة ﻟﻸﻣﺮاض
ﻏﯿﺮ اﻟﻤﻌﺪﯾﺔ ﻓﻲ اﻹﻣﺎرات اﻟﻌﺮﺑﯿﺔ اﻟﻤﺘﺤﺪة.
ﻣﻔﺎھﯿﻢ اﻟﺒﺤﺚ اﻟﺮﺋﯿﺴﯿﺔ :اﻷﻣﺮاض ﻏﯿﺮ اﻟﻤﻌﺪﯾﺔ ،أﻣﺮاض اﻟﻘﻠﺐ واﻷوﻋﯿﺔ اﻟﺪﻣﻮﯾﺔ ،ﻋﻮاﻣﻞ
اﻟﺨﻄﺮ اﻟﻘﻠﺒﯿﺔ ،اﻟﺴﻤﻨﺔ اﻟﻤﻔﺮطﺔ ،ﺳﻜﺮ اﻟﺪم ،ارﺗﻔﺎع ﻧﺴﺒﺔ اﻟﺪھﻮن ﻓﺎﻟﺪم ،ارﺗﻔﺎع ﺿﻐﻂ اﻟﺪم ،اﻟﺴﻤﻨﺔ
اﻟﻤﺮﻛﺰﯾﺔ.
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Chapter 1: Introduction
1.1 The United Arab Emirates
The United Arab Emirates (UAE) is a young country, founded in 1971 by the
late Sheikh Zayed Bin Sultan Al Nahyan. This 47-year-old country is part of the 6 Gulf
Cooperation Council countries, situated in the southeast of the Arabian Peninsula in
southwest Asia on the Arabian Gulf, Figure 1. The UAE, similar to the neighboring
countries, experienced an economic reformation after the discovery and use of their
oil and gas resources.

Kuwait

Bahrain

UAE

Qatar

Saudi Arabia

Yemen

Abu Dhabi

Figure 1: The geography and map of the UAE
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The total area of the country is 83,600 square kilometers with a population of
9.5 million (1). It consists of seven states; Abu Dhabi, Dubai, Sharjah, Ajman, Umm
Al-Quwain and Fujairah. Abu Dhabi Emirate, is the largest Emirate accounting for 87
percent of the total land area. Abu Dhabi has the second largest population, after
Dubai, it is estimated to be around 2 million people where 20% or 550 thousand are
Emirati citizens. Dubai, on the other hand, is 4,114 square kilometers and 2.5 million
people reside in this city. The proportion of Emiratis in the country is 11.5%. The UAE
population is majorly young. Figure 2 displays Abu Dhabi’s unique age distribution
of the Emirati population (2).

MALES

FEMALES

Figure 2: Abu Dhabi's Emirati population by age

The economic burst of the UAE, along with the political and diplomatic
strategies with countries all over the world, transformed the country from a developing
country to one of the most developed countries in the world, with happy and contented
citizens and residents. In 2014, it was noted that the gross domestic product (GDP) of
the UAE increased from AED 6.5 billion in 1971 to AED 1.54 trillion. The World
Bank classifies the UAE as a high-income developed country (1). The World
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Happiness Report (2016-2018) ranked the UAE as number 21 based on their happiness
indicators (3).
The Human Development Index shows the progress the UAE has made in
health, education and income over the last few decades (4). The UAE has moved up
the worldwide index scale from the 62nd place to 30th with a score that exceeded that
of Europe’s as whole. Today, educational attainment is very high with less than 5%
being illiterate.
The experienced economic and industrial development resulted in the wealth
of the national population. This caused a parallel shift from a traditional lifestyle to a
more modernized and urbanized lifestyle, that is characterized by reduced physical
activity and increased consumption of energy-dense food. Consequently, an increase
in rates of obesity and other risk factors was coupled with a rise in noncommunicable
diseases (NCDs). NCDs are conditions that do not result from an acute infection, and
therefore not infectious or “communicable”. These diseases are chronic and are not
cured spontaneously. The characteristics of this group of diseases are complex, have a
long latency period, prolonged course of illness and cause functional impairment of
disability.
1.2 Health in UAE
The life expectancy at birth in the UAE surged to exceed 76 years. Mortality
figures, such as infant, child and maternal mortality rates have improved significantly
from the 70s and 90s to 2010 (5). Causes of premature death and causes of disability
have shuffled across the decades. In the 90s, communicable diseases were in the top
ranks as causes of death, however, decades later in 2017, NCDs, such as cardiovascular
diseases, diabetes, cancer and musculoskeletal disorders took over. The World Health
Organization (WHO) reports that non-communicable diseases (NCDs) account for
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77% of all deaths in UAE (6). From all deaths, cardiovascular diseases account for
40% of the causes, followed by injuries, cancers, and diabetes mellitus. A summary
on the UAE’s health profile is presented in Figure 3.

Figure 3: UAE's causes of death
1.3 Heart disease – the number 1 cause of death in UAE
Heart diseases, or cardiovascular diseases (CVDs), are a group of disorders of
the heart and blood vessels (7). They can be coronary heart disease, cerebrovascular
disease, peripheral arterial disease, or deep vein thrombosis, the types of CVDs are
illustrated in Figure 4. Other forms of CVDs can be congenital, called congenital heart
disease or can be caused by a bacterial infection, called rheumatic heart disease. Heart
attacks and strokes are usually acute events that are caused by accumulated plaque in
veins blocking blood flow to the heart or brain.
CVDs are the number 1 cause of death in the world (8). Globally, it is estimated
that almost 18 million people died of CVD in 2016, which represent 31% of all deaths
worldwide. The most common CVDs that lead to death are heart attack and stroke.
Majority of the CVD deaths occur in low- and middle- income countries. Such diseases
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are preventable by addressing modifiable behavioral risk factors. Such risk factors
include tobacco use, unhealthy diet, physical inactivity and obesity.
CVD is common in the UAE. Loney et al. reported that the UAE has one of
the highest age-standardized death rates for CVD in the world, 308.9 per 100,000 for
males and 203.9 per 100,000 for females (9). Figure 5 compares the trend in ageadjusted prevalence and incidence rates between Global rates and the UAE. The
Statistical Center in Abu Dhabi reported that the death rate by cardiovascular diseases
is 39.7 per 100,000 (10). The ministry of Health and Prevention report (2019) revealed
that cardiovascular disease-related deaths were attributable to acute myocardial
infarction by 22%, followed by cerebrovascular disease, ischemic heart disease and
hypertension (11). A recent report by Al shamsi et al. reported the incidence of CVD
in high risk individuals to be 12.7 per 1000 person years (12). Yusufali observed that
UAE has a higher prevalence of CVD risk factors as opposed to other developed
countries with the deaths in UAE being above average (13).

Figure 4: Types of cardiovascular diseases (14)
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1.4 Diabetes
Diabetes is a chronic disease that arises when the pancreas does not produce
enough insulin or when the body cannot effectively uptake the insulin. Insulin is a
hormone that regulates blood sugar. In diabetes, raised blood sugar, or
hyperglycemia, happens. When this phenomenon persists over time, it may lead to
serious damage in other body systems and complications. There are 2 types of
diabetes; type 1, which is also called as juvenile or childhood-onset, as it arises in
childhood due to deficient insulin production and the etiology is not known. Type 2
diabetes (T2D), also called as adult-onset, results from the body’s insensitivity to
insulin. A third type of diabetes is gestational diabetes, is hyperglycemia during
pregnancy. An intermediate phase between normal and diabetic is called prediabetes or impaired glucose tolerance and impaired fasting glycaemia. This
intermediate phase serves as a transitional phase where the blood glucose is
higher than normal but below the diagnostic value for diabetes definition. People
at this phase are at high risk for T2D but can avoid developing the disease by
the appropriate intervention, such as up taking a healthy diet, physical activity,
avoiding tobacco use, and regular screening and taking medication.
Diabetes numbers have risen from 108 million in the 1980s to 422 million in
2014 (15). The prevalence is rising rapidly in middle- and low- income countries. In
2016, it was estimated that 1.6 million deaths were caused by diabetes. Globally,
diabetes sits on the 7th rank as leading cause of death. Other consequences include
blindness, kidney failure, heart attacks, stroke and lower limb amputation.
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Type 2 diabetes (T2D) is a major public health concern in the UAE. The
International Diabetes Federation ranks four Arab countries in the top 10 globally,
where the United Arab Emirates (UAE) stands on the 8th position on the list, with
more than 1 million cases (16). Figure 5 displays the difference in prevalence and
incidence rates for diabetes globally and in the UAE. A population-wide screening
program conducted in Abu Dhabi Emirate, estimated the prevalence of T2D as 18%
in adults and 27% had prediabetes (17). Age-standardized diabetes and pre-diabetes
prevalence rates were 25% and 30%, respectively (18). In the National Diabetes
Guidelines of 2009, it was reported that T2D prevalence rates reached 19.6% in total,
with 24% in UAE nationals (19). These high rates are threatening, especially in a
young population like the UAE’s.
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Figure 5: Overall age-adjusted global and local prevalence and incidence rates of
Diabetes Mellitus (1990-2017). Global Burden of Disease tool
1.5 Risk factors
NCDs are caused by multiple risk factors. The term “Risk Factor” is defined
as “an aspect of personal behavior or lifestyle, an environmental exposure, or a
hereditary characteristic that is associated with an increase in the occurrence of a
particular disease, injury, or a health condition” (20).
Risk factors can be modifiable or unmodifiable. Modifiable risk factors are
those that can be reduced or controlled by intervention, they include among others,
physical inactivity, tobacco use, alcohol use, and unhealthy diets. Unmodifiable risk
factors are factors that cannot be reduced or controlled by intervention, for instance,

9
age, gender, race, and genetics. The term “metabolic” refer to the biochemical
processes involved in the body’s function, or metabolism. Metabolic risk factors
include raised blood pressure, raised blood lipids levels, elevated blood glucose levels
and overweight and obesity. These risk factors are considered “intermediate” or
secondary to modifiable and unmodifiable risk factors. Eventually, metabolic risk
factors lead to the main chronic diseases; like cardiovascular diseases, and diabetes.
There are other risk factors found to be linked with chronic diseases and are
being studied immensely worldwide. These include the social factors; which include
education, employment, living conditions and family parity. Mental health and
psychosocial stress are also considered factors playing role in disease development.
Other examples of risk factors include alcohol use, medications like chronic use of
Nonsteroidal anti-inflammatory drugs (NSAIDs), women’s health, inflammatory
markers, coagulation, sleep patterns, vitamins and the list keep growing with new
discoveries to links to chronic diseases.
The INTERHEART study, which included data from 52 countries across the
world, showed that smoking, hypertension, high lipoprotein levels, and diabetes
accounted for 76% of the risk of myocardial infarction (21). Other large cohort studies
have also concluded that CVDs are affected by these same main risk factors; smoking,
diabetes, hyperlipidemia, and hypertension (22).
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Figure 6: Causes of chronic diseases (23)
People who develop coronary heart disease typically have more than one risk
factor. The clustering of cardiovascular risk factors begins in youth, young adulthood
and middle age (24, 25). The presence of multiple risk factors simultaneously has been
showed to increase the risk for atherosclerosis development in young and middle-aged
adults and risk of cardiovascular disease in middle age. CARDIA study estimated that
accumulating three or more risk factors were associated with around 2.4-fold increase
in men and 6-fold increase in women in the risk of coronary heart disease after 20
years of follow-up (26). Another study showed that accumulating three or more risk
factors increased the relative risk of developing cardiovascular events from 2.07 (CI
1.86-2.30) to 2.80 (CI 2.48-3.17) when compared to having one risk factor only, in a
6-year follow up (27). According to country incomes, it was concluded that high
income countries had a larger accumulation of cardiovascular risk factors (28).
Interrelationships between pairs of risk factors have been studied previously.
Weight increase was reported to be associated with hyperlipidemia, glycaemia, and
hypertension in young adults (29). Hypertension was reported to be associated with
diabetes (30). In addition, insulin resistance was associated with hypertension, and the
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opposite relationship was established as well (31). Other studies reported an increase
in incident diabetes and hypertension following dyslipidemia (32, 33) .
A Chinese study assessed the effect of lifestyle on the clustering of risk factors
(34). It reported that drinking, physical inactivity and the chronic use of NSAIDs were
associated with the accumulation of cardiovascular risk factors. Drinking increased the
risk by 60%, physical inactivity by 20% and NSAIDs by 2.17-folds. Another study
showed that accumulating risk factors were higher in males and increased with age
(35). The study concluded that interventions should be directed towards the elderly
and people with lower levels of socioeconomic status.
Multiple studies have examined the clustering of risk factors in the context of
metabolic syndrome. Metabolic syndrome describes a combination of risk factors that
increase the risk of developing heart disease, stroke, and type 2 diabetes. The National
Cholesterol Education Program’s Adult Treatment Panel 3 (ATP3) identified
metabolic syndrome as a multiplex risk factor for cardiovascular disease that is
deserving of more clinical attention (36).
In the UAE, only one study described the accumulation of cardiometabolic risk
factors in local population (37). This study was based on military men aged 18-29.
Other studies in the UAE that focused on cardiometabolic risk factors accumulation
were in the context of metabolic syndrome in expatriates, children and adolescents, or
in a specific gender (38-40).
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Chapter 2: Research Problem and Objectives
2.1 Research Problem
The UAE’s rapid urbanization is paralleled by the rise of burden of chronic
noncommunicable diseases (NCDs). NCDs are a cause of great concern in developed
and developing countries. These diseases are caused by the complex interplay of
external factors and genetic predisposition. Many factors, modifiable and nonmodifiable, are reported to have associations with NCD development and
pathogenesis. These factors range from the individual’s health status and family
history to social factors and lifestyle elements.
NCDs are most commonly attributable to cardiometabolic risk factors such as
obesity, hyperglycemia, dyslipidemia, high-blood pressure, and central obesity as well
as behavioral risk factors such as lack of physical activity and smoking.
Socioeconomic factors and family history of disease also play a big role in the
development of NCDs. The prevalence of the cardiometabolic risk factors associated
with NCDs has increased in the UAE and will continue to increase, as demonstrated
by many studies and predicted by projections and future estimates.
Since NCDs are caused by the interplay of risk factors and their accumulation,
it is important to study how these risk factors accumulate before a chronic disease is
established. The majority of local research studied the risk factors only individually.
Most of the epidemiological studies are pre-dated and are either very city specific or
only recruited patients from specific healthcare settings. Moreover, only few reports
have measured the burden of the risk factors. And only fewer studies focused on young
adults, although it has been established that chronic diseases started showing in
younger adults, both world-wide and nationally. Finally, no reports have estimated the
effect of social, lifestyle and family history determinants on cardiometabolic risk
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factors in UAE. This thesis aimed to address the prevalence of cardiometabolic risk
factors and their burden in a large sample of young adults and to study how the social
and behavioral determinants play a role in cardiometabolic abnormalities.
2.2 Research Objectives
The primary aim of this project is to address the epidemiology and burden of
cardiometabolic risk factors causing NCDs, primarily cardiovascular diseases, in a
sample of young Emiratis aged 18 to 40 years. The project has the following three
objectives.
The first objective was to describe the distribution of cardiometabolic risk factors in
this population by:
-

Estimating the crude and age-adjusted prevalence for each cardiometabolic
risk factor by age, gender, social and behavioral determinants

-

Describing the comorbidity of these risk factors; which risk factors co-exist
with others most of the time.

-

Describing the associations among the cardiometabolic risk factors, and with
the other social and behavioral determinants.

The second objective was to describe the burden of cardiometabolic risk factors by:
-

Describing the prevalence of accumulated risk factors for each individual.

-

Estimating the proportions of people having two or more risk factors by age
and gender.

-

Investigating the associations between specific social and behavioral
determinants and the burden of having two or more risk factors.

The third objective was to investigate the effect of BMI on the other cardiometabolic
risk factors and their burden by:
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-

Describing the distribution of each cardiometabolic risk factor within BMI
classes by age and gender.

-

Describing the burden of cardiometabolic risk factors by BMI classes.

-

Investigating the associations between specific social and behavioral
determinants and the burden of having two or more risk factors in each BMI
class.
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Chapter 3: Literature Review
3.1 The cardiometabolic risk factors
Cardiovascular disease (CVD) is the leading cause of mortality worldwide. In
UAE, 40% of the deaths are attributable to CVDs (7). A recent study estimated the
incidence is 12.7 per 1000 person-years, 16.8% in men and 9.0 in women (12). The
main causes of cardiovascular disease can be grouped as cardiometabolic risk factors,
and they include obesity, dysglycemia, dyslipidemia, hypertension, and central
obesity. These cardiometabolic risk factors are affected by modifiable and
unmodifiable causes. Modifiable risk factors include behavioral or lifestyle factors like
smoking and physical inactivity. While unmodifiable risk factors include aging and
family history of NCDs. This chapter reviews the literature on the mentioned risk
factors pertaining to cardiovascular disease in UAE.
3.1.1 Obesity
According to National Clinical Guideline Center, obesity is defined through
measurement of Body Mass Index (BMI) with the report showing the rates of
prevalence of obesity being in an increasing trend (41). Chan and Woo defined obesity
as a condition of abnormal or excess fat accumulation in adipose tissue leading to
health impairment with the BMI being the population-level measure of obesity (42).
In the contemporary health care sector, obesity cases represent increasing issues
contributing to significant health and social difficulties among global populations. The
increasing trend on prevalence is supported by WHO report (43). The report observed
that global obesity has almost tripled since 1975, with 30% of adults aged 18 years
and above being overweight as at 2016 and 13% being obese. This is also evident
among the children where 41 million children globally being obese in 2016.
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Despite the aetiology of obesity being ill-understood, Torres and Nowson
noted that its pathology is based on an increased chronic intake over caloric
expenditure leading to a net gain in calories which is later stored in form of excess fat
in adipose tissues (44). This condition as noted by National Clinical Guideline Center
is directly associated with different conditions such as type 2 diabetes, hypertension,
gallstones and gastro-oesophagal reflux disease and other psychological and
psychiatric morbidities (41). To affirm this, the Health and Social Care Information
Center in the UK had reported that a total of 11,740 inpatients admissions were as a
consequence of a primary diagnosis of obesity in 2011/2012 (45). This is an indicator
that obesity has an immense implication on the well-being of people in modern society.
From an international perspective, obesity epidemic drives up the burden levels
of general non-communicable diseases (NCDs) with more than 40% prevalence rates
(46, 47). This is affirmed by the WHO report that had ranked obesity as a modifiable
risk factor of major NCDs (43). In particular, a report had noted that for the adults
aged between 40 and 59 years with obesity, they suffer from 21 to 85% increased risk
of developing cardiovascular disease and diabetes as opposed to normal weight peers
(48). The report that profiled noncommunicable diseases using country profiles of
2018 equally noted that obesity is linked to an increased risk of hypertension and many
NCDs including diabetes, coronary heart disease, stroke and cancers and conditions
such as obstructive sleep apnoea and osteoarthritis. In this case, individuals suffering
from obesity opting for gastric bypass surgery have an overall 33% reduction in death
rate hence the weight loss being directly linked with a decrease in mortality (49). This
is with obesity leading to an increased risk of more than 13 types of cancer with more
than 630,000 individuals in USA diagnosed with cancer linked with obesity in 2014
and a significant increase with 7% as at 2014 (50). According to Webber et al. 60%
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of the NCDs are as a consequence of obesity which directly contributes to health
concern on individual quality of life, their longevity or lifespan and costs of their health
systems (46).
Despite obesity increasing substantially as the affected individual ages, there
is no specific age that obesity occurs or elicits health implications. Kranjac and
Wagmiller, for instance, pointed out that childhood obesity trends in developed
countries indicate that 10% of all obesity cases arise from childhood (51). Kim et al.
on the other hand pointed on the adolescent and elderly obesity which equally has a
significant implication in the overall obesity cases prevalence (52). In terms of gender
nevertheless, some studies have pointed out that females have a higher prevalence of
obesity as opposed to males (53). This view is supported by Alhyas et al. which noted
that globally, the BMI of adults has significantly increased between 1980 and 2013
from 28.8% to 36.9% in males and 29.8% to 38.0% for the females (54). This
particularly is an influence of the differential fat distribution and the pathophysiology
of the obesity cases.
In the past decade, UAE has reported an increased prevalence of obesity (55).
This is supported by a systematic review that concluded that the cardiovascular
diseases and noncommunicable diseases are directly caused by obesity as a primary
public health priority (9). In UAE, the obesity prevalence has been investigated
through the adoption of distinct strategies for BMI interpretation that show its
prevalence levels. Sulaiman et al. noted that in a study done in UAE over 15 years, a
third of the population had obesity with more than 40% being overweight (56). The
high prevalence of obesity in UAE is also associated with increased cases of NCDs.
For instance, it observed that the risk ratios of type 2 diabetes and hypertension have
increased at a greater rate as opposed to other GCC states (56). This is on top of the
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increasing prevalence of both diabetes and high cholesterol levels in UAE particularly
among the individuals suffering from obesity.
3.1.2 Dysglycemia
Dysglycemia is a term that refers to an abnormality in blood sugar levels. It
includes hyperglycemia, which is prediabetes and type 2 diabetes. It also includes
hypoglycemia or low blood sugar as well (57). Dysglycemia is a widely-spread disease
globally and is increasing at an alarming rate. Prediabetes is the intermediate phase of
hyperglycemia – where blood sugar is above normal but below the diabetes cut-off.
The diagnostic criteria are different across guidelines and countries, however it still
remains a high risk state for developing diabetes (58). The yearly conversion rate from
prediabetes to diabetes is 5-10%. The CDC reports that 1 in 5 adolescents and 1 in 4
young adults are living with prediabetes (59). Interventional studies showed efficacy
in diabetes prevention with a relative risk reduction of 40%-70% in adults with
prediabetes. The CDC National Diabetes Statistics Report suggested that 37% of
American adults above 20 years and 51% of above 65 had prediabetes in 2009-2012
defined by fasting glucose or HbA1c levels (60).
Diabetes is a group of metabolic diseases that is characterized by chronic
hyperglycemia resulting from a defect in insulin secretion, insulin uptake, or both.
Diabetes Mellitus is labeled as “The epidemic of the century” because it is rising to an
alarming epidemic level. Like other NCDs, it involves the interaction between genetic
and environmental factors. Diabetes numbers have risen from 108 million in the 1980s
to 422 million in 2014 (15). The prevalence is rising rapidly in middle- and lowincome countries. In 2016, it was estimated that 1.6 million deaths were caused by
diabetes. Globally, diabetes sits on the 7th rank as leading cause of death.
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The global prevalence of diabetes according to the International Diabetes
Federation (IDF) was 8.3% in 2013 (61). And the number is expected to rise beyond
592 million by 2035 with a 10.1% global prevalence (62). The Middle East and North
Africa region has the highest prevalence of diabetes (10.9%). Low- and middle-income
countries count for 80% of the cases.
Diabetes has been associated with cardiovascular diseases. Patients with
diabetes have 2 to 4 times increased risk of cardiovascular morbidity and 1.5 to 3.6
increase in mortality (63). Moreover, as noted by WHO cardiovascular disease is
widely prevalent among the diabetic patients (64). Interventional as well as
epidemiological studies have also shown that cardiovascular risk factors are present
with pre-diabetic or hyperglycemic patients (65). According to International Diabetes
Federation (IDF), people who have diabetes are two or three times more likely to get
cardiovascular diseases (66). The report published by IDF also noted that 2 to 27
middle-aged individuals among 1000 with type 2 diabetes or other unspecified
diabetes died from cardiovascular diseases.
Ageing is a major risk factor for diabetes. Central obesity and insulin resistance
are preconditions of diabetes and are frequently found in older individuals. Ageing and
diabetes can also be related to the decline in lean body mass and increase in body fat.
The percentage of adolescents and young adults living with prediabetes was higher in
males and participants with obesity (59). Within the global prevalence, there are 14
million more men than women (198 million men vs 184 million women) suffering
from diabetes (59).
Diabetes and prediabetes have been studied in the UAE. The IDF atlas 2019
estimates age-adjusted prevalence rate of diabetes as 16.3% (CI 13.6 – 19.2) (67). The
UAE National Survey Report 2017-2018, published by the Ministry of Health,
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estimated that the prevalence of diabetes in UAE was 11.8%, and the prevalence
among Emirati citizens was 10% (11). Prediabetes was estimated as 11.7% in the
whole population, 9.7% among Emiratis. Another recent report, published in
November 2019, estimated the diabetes prevalence among Emiratis as 21.2% in males
and 23.3% in females, while prediabetes accounted for 17.4% males and 16.7%
females (68). In 2012, a national screening program, called Weqaya, estimated a
prevalence of 27% for prediabetes and 18% for diabetes among nationals (17). The
big difference in prevalence rates across the reports is probably due to the difference
in selected populations and diagnostic markers.
3.1.3 Dyslipidemia
Dyslipidemia is the metabolic abnormality that contributes to a persistent
increase in the plasmatic concentration of cholesterol and triglycerides (69). This
condition can be grouped into three different types which are hypercholesterolemia,
hypertriglyceridemia, and mixed hyperlipidemia all elicited as a consequence of the
elevation of cholesterol and triglycerides compounds. According to Cappi et al. (70)
the condition is a common cause of morbidity globally with the most popular type
being the hypercholesterolemia which is identified as having an overall cholesterol
level of above 5.0 mmol/L or 190 mg/L. The WHO further note that
hypercholesterolemia contributes to approximately 2.6 million (4.5%) global deaths
with 39% of the affected being males and 40% females (71).
Dyslipidemia which is inclusive definition of elevated cholesterol, which is a
lipophilic molecule that is crucial for the body. Cholesterol travels in the blood stream
in lipoprotein molecules: low-density lipoprotein cholesterol (LDL-C) and low highdensity lipoprotein cholesterol (HDL-C). Total cholesterol, LDL-C, HDL-C and
triglycerides represent the lipid profile in the body which constitutes as significant
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modifiable risk factor for NCDs. Dyslipidemia related NCDs had been estimated to
contribute to 65% of the overall deaths with 30% of these deaths being as a
consequence of cardiovascular diseases based on the WHO reports (8). According to
Baghbani-Oskouei et al. (72) the majority of NCDs that are elicited by dyslipidemia
include hypertension, type 2 diabetes and mortality rates globally. Also, dyslipidemia
is identified as a significant contributor in the development of the coronary heart
disease with Peng et al. noting it as cerebrovascular outcomes, while Willey et al.
observed that it is evidenced by the correlation between lipid levels and cardiovascular
diseases (73, 74). This is evidenced by WHO report that has noted that 39% of the
coronary, hypertension, type 2 diabetes and cardiovascular diseases are as a
consequence of the increased prevalence of dyslipidemia (8).
Successful prevention and treatment of dyslipidemia condition ought to be
perceived as a critical segment in the individual cardiovascular prevention
interventions which should be addressed primarily to those with higher risks.
According to Zodda et al. (75) the prevention is nevertheless dependent on the clinical
characteristics of an individual (hypertension and diabetes) and other risk factors
(familiarity, habitual smoking and sedentary lifestyle).
The effect of age and gender differences in the prevalence of dyslipidemia is
evident and unique based on the sociodemographic characteristics of an individual.
For instance, the WHO noted that the global prevalence in 2008 was 37% for the men
and 40% for women (76). In terms of age, the study pointed out that the prevalence
increased by age with the peak prevalence being after age 60 and significantly
prevalent in men under 50 years old than in women. Conversely, Hendrix et al. (77)
study that comprised of wide-array respondents from different sociodemographic
characteristics noted that 65% of dyslipidemia hypertensives were men and 35% being
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women. The study equally noted that majority of the affected patients are aged 64
years which is an average number of population of dyslipidemia hypertensives. These
findings are in line with Li et al. (78) study that found out that 43.3% of individuals
suffering from the condition were men with 38.7% being women.
Currently, dyslipidemia is identified as a critical modifiable risk factor for
cardiovascular disease and the leading cause of mortality in UAE (79). Findings of Al
Sifri et al. (80) study that involved multiple respondents from UAE showed that 85.7%
of all patients suffered from dyslipidemia. These findings were affirmed by Radaideh
et al. (81) study that focused on 74% of 495 patients suffering from dyslipidemia. The
study found that out of these patients, half of them had hypertension (43%) with onethird having diabetes (32.4%). According to the Ministry of Health’s report and
Weqaya, 44% of the population has dyslipidemia (11, 17).
3.1.4 Hypertension
Globally, approximately 7.5 million deaths or 12.8% of the overall annual
deaths are attributed to high blood pressure (82). The WHO projected that by 2025 the
cases of high blood pressure would increase to 1.56 billion adults. Furthermore,
according to the definition by Joint National Committee 8, normal blood pressure is a
systolic blood pressure <120 mm/Hg and diastolic blood pressure <80 mm Hg (83). A
high blood pressure – or hypertension- can be identified as a systolic blood pressure
level of ≥140 mm/Hg of a diastolic BP level ≥ 90 mm/Hg.
The pathology of hypertension is not clearly understood but identified as a
silent killer with minimal symptoms being reported in early stages to the point of
occurrence of severe medical crisis such as heart attack, stroke or chronic kidney
disease (83). Due to lack of awareness on the pathology of hypertension, it is only
through diagnosis that detection can be done. This is affirmed by Ingale and Dixit who
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noted that despite a majority of patients suffering from HBP being asymptomatic, the
patients report suffering from headaches, lightheadedness, vertigo, altered vision and
fainting episodes (84).
From a global perspective, Erem et al. (85) pointed out that hypertension is a
critical public health issue and is considered as a modifiable risk factor for
cardiovascular complications, cerebrovascular disease, and end-stage renal diseases
which are all grouped as NCDs. To sustain this, You et al. (86) described hypertension
as the second largest risk factor leading to disability and death and third leading risk
factor of the total burden of diseases. Additionally, Singh et al. (84) study that
evaluated the prevalence and associated risk factors of hypertension noted that apart
from the coronary heart diseases, it is linked to 70% of the occurrence of heart failure,
peripheral vascular disease, renal impairment, retinal haemorrhage and visual
impairment.
Despite hypertension being prevalent among all people of different ages, it is
directly linked with mortality in the middle and old age (87). In terms of gender, men
have a higher prevalence compared to women, unless the women are menopausal (88).
A study conducted between 1999 to 2004 noted that women had a higher blood
pressure due to high cardiovascular risk factors than men including central obesity and
elevated BMI (89). Also, Blumenthal et al. (89) noted that women had higher systolic
blood pressure as opposed to men with >80% of them being postmenopausal. In regard
to obesity, Ong et al. (90) noted that more than 79% of women who have obesity are
likely to suffer from high blood pressure as opposed to men.
In UAE, the National Epidemiological Study of Hypertension in the UAE
(NESH-UAE) has pointed out that hypertension is higher among the Emiratis aged 30
to 50 years with prevalence being higher in females (54%) as opposed to males (47%)
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(91). This is affirmed by a more recent study by Abdulle et al. (92) that has evidenced
on existence of a high prevalence of hypertension among UAE children and
adolescents with the prevalence being 34.8% for the females and 34.0% for males. The
NCDs prevalence in UAE as noted by Razzak et al. (93) is a significant issue among
the UAE. According to the study, 5% of all the NCDs are a consequence of the
hypertension with the other risk factors being cholesterol and obesity. In terms of
mortality rates, it was noted that a quarter of Dubai Emirati population has in past been
diagnosed with hypertension which contribute to the development of cardiovascular
morbidity and mortality in long term (94). Also, Al-Shamsi et al. (95) pointed out that
the prevalence of chronic kidney diseases and cardiovascular diseases among UAE
nationals has increased by 4.6% in males and 2.8% in females within 9 years, with a
majority of the patients having the hypertension. According to the UAE National
Health survey (2019), hypertension prevalence is 28.8% in 18-40 age group (11).
3.1.5 Central Obesity
In the year 1997, expert consultants on obesity at WHO recognized the medical
significance of abdominal fat mass that is commonly referred to as central obesity,
visceral obesity, or abdominal obesity (96). According to Straznicky, Lambert,
Lambert and Esler (97) central obesity is the result of concentration of Non-Esterified
Fatty Acid (NEFA) that damages glucose disposal that is insulin related. Central
obesity is defined as accumulation of fat in the abdominal area and is measured by
waist circumference, waist-to-stature ratio, and waist-to-hip ratio (98). Worldwide
prevalence of general as well as abdominal or central obesity is increasing rapidly.
Central obesity has been found to be strongly associated with cardiovascular
diseases (99-101). A study conducted by Sahakyan et al. (102) among the adult
population with 15,184 individuals between the ages of 18 to 90 years revealed that a
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person having normal weight but a central obesity has less chances of long-term
survival. Casanueva et al. (100) stated that the frequency of cardiovascular disease
increases with abdominal adiposity. These studies also indicated that the associated
factors of obesity like diabetes mellitus, hypertension, increase the chances of
cardiovascular diseases among individuals.
It was noted that age has significant impact on central obesity (103). Central
obesity was found to increase with age. Moreover, a study conducted by Stevens, Katz
and Huxley (104) revealed that waist-to-hip ratio which is one of the significant
measures of abdominal obesity increases with age. However, abdominal obesity has
also been observed among young adults (105). In addition, studies have also shown
gender as one of the differentiators in central obesity (106, 107). It was revealed that
central obesity has significantly increased among men than women (108). The study
noted that this might be because of better metabolic profile of women than men and
thus fat accumulation becomes less.
Central obesity is not studied frequently like other cardiometabolic risk factors
in the UAE. Hajat et al. (17) estimated central obesity to be 55% in 2012. Sulaiman
et al. (56) compared central obesity in diabetic and non-diabetic UAE nationals and
reported a prevalence of 63% vs 46%, respectively. Al Dhaheri et al.’s (38) study on
metabolic syndrome among young university students (17-25 years) estimated a
prevalence of 18.2% for central obesity. Other multiethnic studies reported by Yusufali
et al. and Malik et al. reported different rates of 43.4% and 24%, respectively (13,
109). All rates mentioned were derived from different cities, populations and
approaches.
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3.2 Other risk factors associated with cardiovascular diseases
3.2.1 Social Factors and family history of NCD
Social factors include the sociodemographic or socioeconomic factors, that
include education, employment and marital status. In this study, family history of
NCDs is considered as a social factor as well.
Socioeconomic status (SES) is not specifically confined to a country’s status
and income. Instead, it refers to a person’s social position in a society. Health
improvements do come with a country’s economic prosperity and it can be translated
in reductions in morbidity and mortality. However, there are substantial inequalities
related to SES (110). The relationship between SES and health is irrespective of a
country’s wealth, due to the Income Inequality Hypothesis.
An individual’s health is influenced by material factors like poverty,
unemployment and poor housing and psychosocial factors like stress and depression
(111). These determinants affect individuals from childhood and continue through life.
This leads to the theory that with a lower personal SES, the worse the health is likely
to be (112).
Indicators of SES on an individual’s level can be in relation to education,
occupation, household crowding, materials ownership, parity, marital status,
neighborhood and the list goes on. The cultural specificity of indicators is challenging
in research; for instance, an indicator can be valid in one country but not the other. For
example, in a high-income country, a car ownership is not an indicator of wealth if
everyone owns a car. In high-income countries, low SES among adults is associated
with high risk of CVD in men and women (113). It was reported that the risk increased
by 55% in men and by 2-folds in women.
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There are a number of studies that have highlighted the importance of social
factors such as education and occupation and their relationship with metabolic
syndrome (110, 114). Although the cause and effect relationship between education
and cardiovascular risk factors are complex, studies have shown that the higher the
education level of the individuals is, the greater is the chance of adequate nutrition
(115). With proper education, individuals are more aware of good nutritional habits
and are less likely to have injurious health habits like smoking or alcohol consumption
that reduces the chances of hypertension, diabetes, and obesity (116, 117). Workrelated factors have different effects on health. For instance, having an income can
increase health quality by being able to healthy foods, but the stress and demands on
a job can cause negative health effects. Job stress increased CVD risk by 50% (118).
Marital status is one of the social determinants that has an influence on health.
A meta-analysis on the effect of marital status on cardiovascular disease was led by
Wong et al. included 34 studies with more than 2 million pooled participants (119).
The study concluded that compared to married individuals, being unmarried (never
married, divorced or widowed) increased the odds of CVD by 42% and coronary heart
disease (CHD) by 16%. It also affected the prognosis after CVD, where being
unmarried increased the odds of CHD-death and stroke-death by 43% and 55%,
respectively. On the other hand, other studies showed that marital status has been
reported to be associated with the early stages and progression of cardiovascular
disease, an association that may stem partially from the effect of marital quality on
metabolic factors. In a study that measured the effect of marriage quality on metabolic
disease showed that women in high-quality marriages are at lower risk of developing
metabolic syndrome (120).
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There has been limited research in the context of the UAE and the socioeconomic factors that causes cardiovascular diseases. One patient-based study done in
hospitals of UAE and Saudi Arabia concluded that patients from rural centers were
more likely to have diabetes, hypertension, dyslipidemia, coronary artery disease and
percutaneous coronary intervention (121). After adjustment for confounders, it was
concluded that CHD increased by 2.4 folds for people living in rural areas. Higher
income was also associated with an increased CHD risk by 7-folds. Unemployment
was associated with a 2.21-fold increase in CHD risk. Khafaji et al. (122) evaluated
the marital status and patient outcome in patients with acute coronary syndrome in the
UAE. It was reported that widowed patients were more likely to have diabetes and
hypertension, but less likely to be smokers.
The family history of the cardiovascular diseases influences the risks of
metabolic diseases based on the number and age of first-degree relatives affected.
Family history identifies the medical and health information of people in a similar
lineage. The World Heart Federation (WHF) states that if a first-degree relative
suffered from a heart attack before the age of 55 for men, or 65 for women, the subject
is at greater risk of developing the disease (123). If both parents suffered heart disease,
this could increase the risk by 50%. Research studies established a genetic contributor
for hypertension, dyslipidemia, and hyperglycemia. According to Kolber and
Scrimshaw, the siblings of patients with cardiovascular diseases have a 40% risk
increase (124). The study also noted that offspring of parents with premature
cardiovascular diseases have 60% to 75% increase in the risks.
A study conducted on the Framingham cohort concluded that offspring of
parents with cardiovascular disease had a 60-75% increase in relative risk for suffering
of cardiovascular disease (124). This means that family history is an independent risk
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factor for cardiovascular diseases. This informs on its applicability as a tool for
screening in identifying individuals particularly the asymptomatic young adults with
increased risks of cardiovascular diseases. The relevance of identifying the family
history of metabolic diseases has been known to influence people's lifestyle changes,
enhancing individual empowerment and influencing clinical intervention (125). The
awareness of the family history of cardiovascular diseases should not be sufficient
determinant in altering individual health-related behaviors (126). There is a need for
future studies to focus on explaining the process in which family history of
cardiovascular diseases or perceived cardiovascular risk can be utilized in informing a
change in health-related behavior changes.
In UAE, limited research has evidently studied the family history of metabolic
diseases and how this influences cardiovascular diseases. One study that was designed
to explore awareness in Emirati women addressed that 63% of women in their sample
were of that family history plays a role in heart disease (127). Another study touched
upon family history and diabetes; it showed that having a family history of diabetes
significantly increased the prevalence for diabetes in subjects in certain ethnicities
(68).
3.2.2 Smoking
According to the WHO, smoking and the use of tobacco are one of the major
causes of cardiovascular disease (128). Tobacco kills 50% of its users, and is
responsible for 8 million deaths each year. Eighty percent of smokers live in low- and
middle-income countries. A collaborating report by the WHO and World Heart
Federation stated that 10% of all the deaths related to cardiovascular disease are related
to tobacco consumption (129). The report also revealed that a lack of awareness about
the harmful effect of tobacco consumption is increasingly causing risks to
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cardiovascular diseases and resulting in an increasing number of deaths. More recently
a study conducted by UK Biobank among 472,000 participants noted that smoking is
one of the significant causes for cardiovascular diseases (130). In particular, the study
noted that people smoking 20 or more cigarettes every day are more prone to heart
attacks. However, in contrast to the study conducted by UK Biobank, National Health
Services (NHS) noted even one cigarette a day increases the chances of stroke or other
kinds of heart diseases by 40% (131). In addition, the study reported that smoking one
cigarette a day increases risks for heart diseases by 48% among the males and 57%
among the females. Thus, women smokers were found to be more prone to having
heart disease than men.
Furthermore, the Centre for Disease Control and Prevention (CDC) noted how
smoking exposes individuals to toxic substances and makes them more susceptible to
cardiovascular diseases (132). It was noted that the chemicals contained in the
cigarettes causes swell and inflammation in the cells along the line of the blood vessels
that narrows down the vessels causing respiratory problems and cardiovascular
conditions. Atherosclerosis, Peripheral Arterial Disease (PAD), heart attacks or stroke,
Coronary Heart Disease are some of the common cardiovascular conditions caused
due to smoking. The NHS also noted that smoking is one of the significant risk factors
that cause Coronary Heart Disease (133). The carbon monoxide and nicotine that emits
from cigarette smoking causes strain in the heart causing faster heartbeat. These toxic
substances also increase the risk of blood coagulation. According to NHS smoking
cigarettes increases the chance of heart disease by nearly 24% by damaging coronary
arteries. Recently a study conducted by Banks et al. (134) noted that tobacco is one of
the leading risk factors for cardiovascular diseases and heart failure. It also found an
association of Paroxysmal tachycardia or irregular heartbeat.
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According to the WHO, cardiovascular diseases are one of the major causes of
death in the UAE and tobacco use has been identified as one of the major causes (6).
The data published by WHO also predicted a rising trend of tobacco smoking among
men till 2025. The World Tobacco Atlas, that analyzes the use of tobacco and its
consequences, revealed that 27 deaths that are happening weekly in the UAE are
associated with tobacco consumption and its related diseases (135). The atlas reported
that 21.6% of male adults (above 15 years) are smokers, and only 1.9% of women are
smokers. The 2018 National Healthy Survey reported that 15.7% in males and 2.4%
in women are smokers. In the pilot study of the UAE Healthy Future Study cohort,
smoking prevalence was reported to be 36% in men and 3% in women (136). After
cotinine testing, it was verified rates were 42% in men and 9% in women. Dual and
poly-smoking of different types of tobacco (Cigarettes, Shisha, or Midwakh) were also
common.
3.2.3 Physical inactivity
Physical inactivity is an important risk factor in developing CVDs (137).
Physical activities elicit positive implications on metabolic control measured by
HbA1c, blood glucose, or insulin sensitivity all linked to cardiovascular diseases
(138), and regular exercises positively improve cardio-respiratory fitness, muscular
strength, and endurance, body mass and fat composition. Physical activity plays
important active and passive roles in the prevention of coronary artery disease.
Epidemiological studies observed a dose-response relationship where the risk for
cardiovascular events reduced by 20% (139). Exercise was shown to improve
endothelial function, slow the progression of cardiovascular stenosis and myocardial
perfusion. Additionally, sedentary behavior is considered an important risk factor for
CVD, independent of physical activity levels (140).
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In the Middle East, a study by Gehani(141), evaluating the risk factors of
myocardial infarction, physical inactivity was cited as one of the 9 major causative
factors of heart disease mortality. The study summarized that cardiovascular risk
factors have a prevalence inversely linked to physical activity levels. Such findings
informed the American College of Sports Medicine (ACSM), Centers for Disease
Control and Prevention (CDC) and other professional and health organization to
develop position statements (142). These statements offer recommendations for
physical activities aimed at improving health outcomes. According to Smith et al.
(143), these recommendations span past aerobic activity benefits and other physical
activity components such as strength training and flexibility.
A study by Razzak et al. (93) that focused on evaluating the prevalence and
risk factors of cardiovascular disease in UAE provided relevant findings. In a study
conducted in Dubai, 37.3% of the patients with cardiovascular diseases were
physically inactive (13). Increase physical activities in youth and young adults was
recommended in study of university students in UAE (144). There is a need to establish
interventions for promoting lifestyle changes by adolescents and to enhance their
physical activities (145). Loney et al. (9) study based in UAE recommended aspects
of surveillance and monitoring, research, training and federal legislation to focus on
areas of physical activities. In a more detailed approach, in the context of UAE, there
is a need for strategies to be put in place for establishing a national public health
program (146). There however exists a research gap in UAE as there is no study that
has directly focused on the evaluation of the relationship between the inactivity and
cardiovascular complications.
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Chapter 4: Methods
4.1 Study Population
The study sample is retrieved from the UAE Healthy Future Study (UAEHFS)
(147). This study is designed as a prospective cohort study that is recruiting UAE
national volunteers from the general population aged 18 – 40. The target size is 20,000
nationals to be followed-up for years ahead to examine the association between
multiple exposures, including environmental, lifestyle, and genetic risk factors, to noncommunicable diseases. Participants recruitment is based on convenience sampling
where volunteers are invited to participate in the study. Until December 2018,
recruitment took place across 7 clinical research centers located in Abu Dhabi and Al
Ain; Zayed Military Primary Healthcare Center, Abu Dhabi Blood Bank, Al Nahyan
Military Camp, Healthpoint Hospital, Cleveland Clinic Abu Dhabi, United Arab
Emirates University (UAEU), and Al Ain Blood Bank.
This project was based on the cross-sectional analysis of baseline data from
5,167 participants of the UAEHFS cohort, recruited between February 2016 and
December 2018. Subjects were Emirati nationals aged 18 up to 40 years. All
participants are required to give an informed consent. Only participants that suffer any
acute infection at the time of recruitment and women that are pregnant are excluded
from the study.
The UAEHFS is conducted in accordance with the principals of the Declaration
of Helsinki and in conformity with the ICH Guidelines for Good Clinical Practice
(CPMP/ICH/135/95) July 1996. The informed consent and all data collection means
were approved by the Research Ethics Committees (REC)/ Institutional Review
Boards (IRB), reference number 0072017R. For confidential sensitive data, the
participants were assigned a unique research number. Questionnaire responses,
physical measures and lab results were maintained under the unique research number,

34
at the NYUAD data management center. No individual identifiable information was
included in this research.
4.2 Data Collection
At baseline, participants answered a questionnaire, underwent physical
measurements and gave biological samples. The self-completed electronic
questionnaire collected information on risk factors that pertain to NCD development.
The questions explored socio-demographic factors, general health, physical activity,
tobacco use, early life exposures and family history. A copy of the detailed
questionnaire is in appendix 1. The subsequent steps of physical assessments included
measuring blood pressure, anthropometric measures and body composition. The final
step was to give 8 ml of venous blood.
4.2.1 Social factors
Socio-demographic elements like sex, age, employment status, marital status,
and educational accomplishment were collected through the electronic questionnaire.
Employment status was then summarized as employed, unemployed or current
student. Marital status captured whether a person is single, married, widowed or
divorced. Latest educational attainment had a range of answers from uneducated,
elementary, primary, secondary to undergraduate and graduate degrees. The answers
were later categorized to two; high school and below or college and above.
Of the unmodifiable risk factors, family history of NCDs was the only element
that was captured at the time. Multiple questions were designed to collect the maternal
and paternal health history. The parental diseases were heart disease, stroke, diabetes,
obesity, and high cholesterol. Therefore, the family history was categorized as having
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family history (if one or more of the diseases or risk factors) and no family history of
chronic disease
4.2.2 Behavioral factors
Lifestyle or Behavioral factors such as smoking and physical activity were
assessed through the questionnaire. Different smoking methods like cigarette smoking,
traditional pipe (midwakh) and water pipe (shisha) were covered.
Physical activity intensity and frequency questions are adopted from the
WHO’s Global Physical Activity Questionnaire (GPAQ) (148). This is a validated tool
that covers several components of physical activity, such as intensity, duration and
frequency. The GPAQ collected physical activity information across 3 domains:
activity at work, travel to and from places, and recreational activities. The GPAQ
output was used to calculate the metabolic equivalents (METs) to further indicate
whether a person’s physical activity is categorized as high, moderate or low.
4.2.3 Physical measurements
Weight and height were measured by a clinical research nurse. Height was
measured using a stadiometer (Seca, Germany). Participants were asked to put their
back against the vertical scale, keep feet parallel to each other, toes pointing forward
and soles flat on the platform. All four contact points (back of the head, shoulder
blades, buttocks, and heels) made contact with the backboard. The participant’s head
is gently, aligned in the Frankfort Plane, so that they are looking straight forward with
their ear holes in same horizontal plane as the lower border of their eye sockets. The
height is read in centimeters at the end of inhalation; the participant is asked to take a
deep breath in and hold this position during measurement.
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Weight was measured by using the Tanita MC-780 MA body composition
analyzer (Tanita Inc, Tokyo, Japan). The device works by passing an imperceptible
current through the body, via the arms and legs and the results are recorded
electronically. Participants with a pacemaker or an electrical medical implant were
excluded from standing on the device. Body mass index (BMI) was automatically
calculated, via the Tanita, by dividing weight by height in meters squared (kg/m2).
Waist and hip circumferences are measured by the SECA standardized
measuring tape following the WHO STEPwise Approach to Surveillance (STEPS)
protocol (149). Waist circumference was measured approximately at midpoint of the
lower margin of the last palpable rib and the top of the iliac crest and recorded to the
nearest centimeter. Hip circumference was measurement at the widest portion of the
buttocks and similarly recorded to the nearest centimeter.

Figure 7: Waist and hip circumferences
Blood pressure was measured by SphygmoCor Xcel device (Atcor medical,
New South Wales, Australia), which electronically measures brachial systolic and
diastolic pressures. Brachial blood pressure if measured from the left arm. The right
arm is only used if the left is not practical e.g. amputee. It is taken twice or 3 times,
with a minute break in between, then the average is taken.
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4.2.4 Blood samples
Blood samples were collected by venipuncture using a 21-gauge butterfly
needle taped to the skin. Plasma was collected in EDTA Vacutainers (8ml) from
Becton Dickinson. Random and fasting blood was collected into SST tube that is
centrifuged at 3000 – 3500 RPM for 10 minutes. The sample was then stored at 4°C
and transported to the lab, then analyzed using UniCel DxC 600 System. The lipid
panel included total cholesterol, LDL and HDL levels, and triglycerides. Analysis of
HbA1C and glucose was done using UniCel® DxC 600 System.
4.3 Cardiometabolic risk factors definition criteria
4.3.1 Obesity
According to the WHO definitions, a BMI of less than 25 kg/m2 is considered
normal, and a BMI that lies between 25 and 30 kg/m2 is considered overweight (150).
An individual whose BMI lies above 30 kg/m2 is considered obese.
4.3.2 Dysglycemia
Diabetes was defined as self-reporting diabetes or insulin use in the
questionnaire, a test of HbA1c of ≥ 6.5%, or glucose ≥ 126 mg/dL for fasting samples
(151, 152). Prediabetes was defined as having HbA1c level between 5.7% and 6.5%
or fasting glucose between 100 and 126 mg/dL (152). Both diabetes and prediabetes
cases were categorized as abnormal glycemic status, or “dysglycemia”.
4.3.3 Dyslipidemia
Dyslipidemia is defined as either self-reported history of abnormal cholesterol
level, or taking a lipid-controlling medication or having an abnormal level of any of
the following; LDL cholesterol level of ≥ 130 mg/dL, HDL cholesterol level of ≤ 40
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mg/dL for men or ≤ 50 mg/dL for women, Total Cholesterol ≥200 mg/dL or
Triglycerides ≥ 150 mg/dL for fasting samples and ≥ 175 mg/dL for random samples
(153, 154) .
4.3.4 Hypertension
Elevated blood pressure, or hypertension, is defined as having a blood pressure
reading of above 140/90 according to the American Heart Association guidelines
(155). Hypertension is also defined as having self-reported “hypertensive” on the
questionnaire and/or whether they are taking blood pressure-controlling medication.
4.3.5 Central obesity
Central obesity is indicated if the waist to hip ratio is equal to or greater than
0.85 for women and equal to or greater than 0.9 for men (96). A summary of the data
collection methods is summarized in Table 1.
Table 1: Summary of data collection methods
Method of collection
-

Self-reported
questionnaire

-

Physical
Measurements

-

Blood sample

Variable
-

Sociodemographic data
Health data
Smoking
Physical activity
Family history
Blood pressure
Anthropometric measurements
(height, weight, waist and hip circumferences)
HbA1c
Glucose
Lipid panel

4.4 Sample size
The power of a study refers to its ability to demonstrate an association if one
exists. An a priori power analysis was used to determine the necessary total sample
n = Z2 P (1 - P)
d2
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size given a desired α level, a desired power level (1-β) and an anticipated prevalence
to be detected with desired precision. The calculations were performed using the
formula:
Where n is the sample size, Z is the Z statistic for a level of confidence, P is
the expected prevalence or proportion, and d is precision. The sample size (n= 384)
was calculated based on the possibility to detect a prevalence of 50% with a precision
(d)=0.05, power=0.8, and confidence level=0.95. The total available sample size
(n=5,126) is sufficient to detect a 50% prevalence with 80% power, and 5%
significance level for more than 10 strata or subgroups (gender by five age groups).
4.5 Statistical Analyses
Baseline characteristics of the study participants were presented overall, and
by gender, BMI categories, and cardiometabolic risk factors groups. Categorical data
was presented as frequencies and percentages and continuous variables were presented
as means ± standard deviation. The frequencies and percentages were tested for
significance of any differences in distribution between two or more groups using chisquare and Fisher’s exact tests. For continuous variables, differences in means were
measured by t-tests and one-way ANOVA tests for normally distributed data. Missing
data were not replaced.
Age-adjusted prevalence rates were estimated using logistic models and
presented with their 95% confidence intervals (CI). The age-adjusted rates were
estimated for the overall prevalence of each CRFs and for the prevalence of different
sociodemographic and lifestyle risk factors within each cardiometabolic risk factor.
The crude and age-adjusted prevalence rates were also estimated for cardiometabolic
risk factors by BMI categories. For age-standardization, population age values from
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the Statistics Center Abu Dhabi (2018) were used to derive age-standardized
prevalence rates (2).
The burden of CRFs was defined and estimated as number of risk factors per
individual. The maximum number of risk factors was five per individual.
Cardiometabolic risk factors were then grouped to form two burden groups; “0-1” and
“≥ 2” risk factors. Characteristics of these groups were presented and examined for
differences by age and gender. The burden groups were also displayed in graphic
representations. To investigate the burden of CRFs by BMI categories, the
cardiometabolic risk factors excluding obesity were then grouped to form “0-1” and
“≥ 2” risk factors burden groups. Characteristics of these groups were also presented
and examined for differences by age, gender, and BMI categories (normal, overweight,
and obese).
Associations between the different sociodemographic and lifestyle risk factors
(exposures) and the individual and grouped cardiometabolic risk factors (outcome)
were evaluated using univariate and multivariate logistic regression analyses. Age,
gender, social and behavioral factors were all adjusted for in the multivariate models.
For example, for estimating the independent association of a social factor with obesity
as an outcome, the multivariate model will include as covariates other cardiometabolic
risk factors in the model with the exposure variable; dysglycemia, dyslipidemia,
hypertension and central obesity, along with age, gender and other social and
behavioral factors. This was repeated for each cardiometabolic risk factor and the
burden of CRFs as dependent variables. The associations were also evaluated
stratifying by gender and BMI categories. Crude and adjusted Odds Ratios (OR) with
their 95% CIs were reported.
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The analyses were performed using Stata 15 software (StataCorp. 2017. Stata
Statistical Software: Release 15. College Station, TX: StataCorp LLC). The
significance level of the statistical tests was set at 5%.
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Chapter 5: Results
5.1 Objective 1: Describe the distribution of cardiometabolic risk factors in this
population
Overall, 5,167 subjects aged between of 18 to 40 years were recruited from
February 2016 to December 2018 and had relevant data. Participants were all Emiratis
coming from different cities; with the majority (around 70%) from Abu Dhabi Emirate.
Complete self-reported data was available for up to 85% of the participants, depending
on data point concerned. Complete body measurements including anthropometrics and
blood pressure was available for 94% of the sample. Finally, complete blood sample
testing was available for 98% of the sample.
Table 2 summarizes the population’s social and behavioral characteristics. The
study sample included 38% females and 62% males. The mean age for the population
was 25.7 years with a median age of 24 years. The age distribution was significantly
different between women and men. Women were generally younger in the sample,
with a mean age of 24.5 years, median age 22, while men had a mean age of 26.4 years,
with a median age of 25. The majority of participants were below 25 years old (Figure
9). The social factors included sociodemographic characteristics and family history of
NCDs. The sociodemographic characteristics of the population were described based
on three determinants; marital status, employment status and latest education degree
attainment. Most of the participants were single (64%) and employed (54%). Half of
the participants had college or post-graduate degree while the other half had a highschool diploma or below. Among females, 75% were single and most of them were
students while 56% of men were single and 68% employed. Family history of NCDs
was reported by 56% of the overall population.
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Table 2: Social and behavioral characteristics of the participants population.
OVERALL

MEN

WOMEN

Pvalue

N= 5,167
3,202 (62%)
1,965 (38%)
Age (years), mean (SD)
25.7 (6.2)
26.4 (5.9)
24.5 (6.3)
0.00
18-<20
872 (16.9%)
374 (11.7%)
498 (25.3%)
20-<25
1,824 (35.3%)
1,091 (34.1%)
733 (37.3%)
25-<30
1,068 (20.7%)
778 (24.3%)
290 (14.8%)
30-<35
784 (15.2%)
563 (17.6%)
221 (11.3%)
35-40
619 (12%)
396 (12.4%)
223 (11.4%)
Marital status
0.00
N
4,409
2,709
1,700
Single
2,804 (63.6%)
1,522 (56.2%)
1,282 (75.4%)
Married
1,497 (34%)
1,144 (42.2%)
353 (20.8%)
Divorced/widowed
108 (2.5%)
43 (1.6%)
65 (3.8%)
Employment
0.00
N
3,668
2,240
1,428
Employed
1,978 (53.9%)
1,535 (68.5%)
443 (31%)
Students
1,032 (28.1%)
399 (17.8%)
633 (44.3%)
Unemployed
658 (17.9%)
306 (13.7%)
352 (24.7%)
Education level
0.032
N
4,310
2,657
1,653
≤ high school
2,326 (54%)
1,468 (55.3%)
858 (51.9%)
≥ college
1,984 (46%)
1,189 (44.8%)
795 (48.1)
Family history of NCD
0.00
N
5,058
3,136
1,922
No
2,228 (44.1%)
1,459 (46.5%)
769 (40%)
Yes
2,830 (56%)
1,677 (53.5%)
1,153 (60%)
Smoking
N
3,927
2,389
1,538
Non-smoker:
2,628 (66.9%)
1,170 (49%)
1,458 (94.8%)
0.00
Current smoker:
1,299 (33.1%)
1,219 (51%)
80 (5.2%)
Cigarette
666 (17.7%)
643 (28.5%)
23 (1.5%)
Midwakh
802 (21.2%)
779 (34.3%)
23 (1.5%)
Shisha
791 (21.2%)
722 (32.3%)
69 (4.6%)
Physical activity
N
2,341
1,393
948
Metabolic Equivalent
(minutes/week), mean (SD) 5514.3 (6306.8) 6456.4 (7003.2) 4129.9 (4792.4) 0.00
Low
1,894 (80.9%)
1,119 (80.3%)
775 (81.8%)
0.00
Moderate
189 (8.1%)
95 (6.8%)
94 (9.9%)
High
258 (11%)
179 (12.9%)
79 (8.3)
Data is presented as mean values with standard deviation (SD) or frequency numbers (N) and
percentages (%). P-values are derived from t-tests and chi-square tests.

Smoking is reported in 33% of the population. Of which, 17% were smoking
cigarettes, 21% smoking midwakh and 21% smoking shisha (water-pipe). Among
women that smoked, smoking shisha was found more popular than smoking other

44
types of tobacco. Men smoked the 3 types almost similarly. The majority of smokers
smoked a single type of tobacco, men tended to smoke multiple types more than
women. For physical activity, around 81% were categorized as performing lowphysical activity and 19% as moderate-to-high physical activity. A similar distribution
was seen among men and women.
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Figure 8: Age distribution of the participants

The cardiometabolic characteristics of the study sample are presented in Tables
3 and 4. The mean BMI in the sample was 26.9 kg/m2, and it was lower in women than
men. Two-thirds of the sample were either overweight (30.5%) or obese (27.2%). In
women, the proportions were 23.6% for overweight and 22.6% for obesity. In men,
they were 35% and 30.1% for overweight and obesity, respectively.
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Table 3: Mean values of cardiometabolic markers of the participants

Cardiometabolic markers

Women,
Overall,
Men,
PMean (SD)
Mean (SD) Mean (SD)
value

Body Mass Index (BMI), Kg/m2
Waist – hip ratio

26.9 (6.3)

27.7 (6.0)

25.8 (6.6)

0.00

0.82 (0.09) 0.87 (0.07)

0.77 (0.08)

0.00

Systolic blood pressure, mmHg

126 (14.1) 131.2 (13.1) 117.8 (11.6) 0.00

Diastolic blood pressure, mmHg

78 (77.7)

80.3 (10.2)

74.3 (8.6)

0.00

Low-density lipoprotein (LDL),
mg/dL

115.9 (34.0) 122 (35.8) 105.9 (28.1) 0.00

High-density lipoprotein (HDL),
mg/dL

48.4 (12.9) 43.9 (10.6)

55.7 (13.0)

0.00

Total cholesterol, mg/dL

182.5 (36.0) 185.8 (38.6) 177 (30.3)

0.00

Triglycerides (TG), mg/dL

103.9 (77.6) 118.8 (86.0) 79.3 (52.8)

0.00

Glycated hemoglobin (HbA1c), %

5.26 (0.66) 5.29 (0.71)

5.21 (0.58)

0.00

88.8 (22.3)

0.00

Fasting blood glucose (FBG), mg/dL

94.3 (25)

96.4 (25.7)

Data is presented as means (Standard deviation). P-values are derived from t-tests.

Based on HbA1c analysis, 6.5% of the sample had prediabetes and 1.9% had
diabetes. Fasting serum glucose yielded a rate of 17.8% for prediabetes and 2.7% for
diabetes. Together; glycated hemoglobin, fasting blood glucose and self-reported
diagnosis or medication identified prediabetes prevalence as 8.7% and diabetes as
3.9%. Men had a higher proportion of prediabetes (10.6% vs 5.7%) and diabetes (4.0%
vs 3.6%) than women. The overall prevalence of dysglycemia was 12.4%. All lipid
levels were significantly higher in men than women, with the exception of HDL (Table
4). Dyslipidemia was reported in 61.7% of the study sample, and it was higher in men
than women. The mean systolic and diastolic blood pressures were significantly
different between men and women. The overall prevalence of hypertension was
observed in 22.9% of the sample; 31% in men and 9.9% in women. Twenty-four
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percent of the population had central obesity. One-third of men had an increased waistto-hip ratio, while only 13.9% of women had that condition.

Table 4: Cardiometabolic characteristics of the participants

OBESITY:
N
Normal
Overweight
Obese
GLYCEMIC ROFILE
Based on HbA1c
N
Pre-diabetes
Diabetes
Based on Fasting Glucose
N
Pre-diabetes
Diabetes
Self-reported Diabetes
Use of insulin
Pre-diabetes
Diabetes
Dysglycemia
LIPID PROFILE
N
High LDL
Low HDL
High total cholesterol
High TG
Self-reported Dyslipidemia
Self-reported use of lipid
lowering medication
Dyslipidemia
BLOOD PRESSURE
Hypertension based on
measurement
Self-reported hypertension

Overall,
N (%)

Men,
N (%)

Women,
N (%)

Pvalue

4,872
2,064 (42.4%)
1,485 (30.5%)
1,323 (27.2%)

2,955
1,033 (35%)
1,033 (35%)
889 (30.1%)

1,917
1,031 (53.8%)
452 (23.6%)
434 (22.6%)

0.00
0.00
0.00

5,078
332 (6.5%)
96 (1.9%)

3,156
227 (7.2%)
68 (2.2%)

1,922
105 (5.5%)
28 (1.5%)

0.01
0.01

1,065
190 (17.8%)
29 (2.7%)
145/3,878
(3.7%)
60/158 (38%)
449 (8.7%)
199 (3.9%)
648 (12.4%)

769
164 (21.3%)
24 (3.1%)

296
26 (8.8%)
5 (1.7%)

0.00
0.00

91/2,352 (3.9%)

54/1,526 (3.5%)

0.596

35/96 (36.5%)
338 (10.6%)
128 (4.0%)
466 (14.6%)

25/62 (40.3%)
111 (5.7%)
71 (3.6%)
182 (9.3%)

0.002
0.00
0.00
0.00

5,078
1,802 (35.4%)
2,231 (43.8%)
1,723 (33.9%)
1,174 (23.1%)
592/3,802
(15.6%)

3,155
1,341 (42.5%)
1,436 (45.5%)
1,201 (38.0%)
889 (28.2%)
396/2,308
(17.2%)

1,923
461 (23.9%)
795 (41.2%)
522 (27.1%)
285 (14.8%)
196/1,494
(13.1%)

83/597 (13.9%)

62/15.6 (15.6%)

21/200 (10.5%)

0.088

3,188 (61.7%)

2,127 (66.4%)

1,061 (54%)

0.00

937/4,838
(19.4%)
326/3,817
(8.5%)
110/341
(32.3%)
1,108 (22.9%)

826/2,962
(27.9%)
234 /2,323
(10.1%)

111/1,876 (5.9%)

0.00

92/1,494 (6.2%)

0.00

33/102 (32.4%)

0.98

187 (9.9%)

0.00

1,880
261 (13.9%)

0.00

Self-reported use of
77/239 (32.2%)
medication
Hypertension
921 (31%)
CENTRAL OBESITY
N
4,818
2,938
Central obesity
1,170 (24.3%)
909 (30.9%)
Data is presented as frequency numbers and percentages (%).

0.00
0.003
0.00
0.00
0.001
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Table 5 summarizes the crude, age-adjusted, and age-standardized prevalence
rates for the risk factors. Across all risk factors, males had a higher prevalence than
females, and the difference was consistently significant. The prevalence for each of
the five major cardiometabolic risk factors change significantly across age groups in
men and women, as visualized in Figure 9. The age-adjusted distribution of the
metabolic risk factors was assessed within the social and behavioral determinants in
men and women as presented in Table 6.

Table 5: Crude, age-adjusted, and age-standardized prevalence rates of
cardiometabolic risk factors in the participants
TOTAL POPULATION
Crude
27.2 (25.9 – 28.4)
12.5 (11.7 – 13.5)
61.7 (60.4 – 63.0)
22.9 (21.7 – 24.1)
24.3 (23.1 – 25.5)

Age-adjusted
Age-standardized*
Obesity
26.5 (25.2 – 27.7)
30.2 (28.9 - 31.7)
Dysglycemia
11.7 (10.8 – 12.7)
14.6 (13.5 – 15.7)
Dyslipidemia
62.7 (61.3 – 64.0)
66.3 (65.0 – 67.6)
Hypertension
22.4 (21.2 – 23.6)
25.0 (23.7 - 26.4)
Central obesity
22.5 (21.3 – 23.8)
29.0 (27.6 - 30.4)
MEN
Crude
Age-adjusted
Age-standardized*
Obesity
30.1 (28.5 - 31.8)
29.7 (28 – 31.4)
32.0 (30.3 - 33.8)
Dysglycemia
14.6 (13.4 – 15.8)
14.0 (12.7 – 15.2)
16.1 (14.8 – 17.5)
Dyslipidemia
68.0 (66.3 – 69.7)
66.4 (64.8 – 68.0)
70.0 (68.5 – 71.5)
Hypertension
31.0 (29.4 - 32.7)
30.9 (29.2 – 32.6)
32.1 (30.4 - 33.9)
Central obesity
30.9 (29.3 - 32.6)
29.6 (27.9 – 31.3)
34.8 (33.0 - 36.6)
WOMEN
Crude
Age-adjusted
Age-standardized*
Obesity
21.6 (19.7 – 23.5)
22.6 (20.8 - 24.6)
27.4 (25.1 - 29.8)
Dysglycemia
9.3 (8.1 – 10.6)
8.3 (7.0 – 9.6)
11.6 (10.0 – 13.5)
Dyslipidemia
54.0 (51.8 – 56.2)
54.2 (52.0 – 56.5)
58.7 (56.3 – 61.2)
Hypertension
9.9 (8.7 - 11.4)
9.2 (7.8 – 10.5)
12.1 (10.5 - 14.0)
Central obesity
13.9 (12.4 - 15.5)
12.5 (10.9 – 14.0)
17.9 (15.9 - 20.1)
Data is presented as prevalence % (confidence intervals)
*Age-standardized rates were estimated using the Abu Dhabi population consensus from
Statistical Center Abu Dhabi.Detailed prevalence rates of prediabetes, diabetes, and each
lipid marker are in Appendix 2.
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Figure 9: Cardiometabolic risk factors distribution across age groups.

49
Table 6: Age-adjusted prevalence (95% CI) of cardiometabolic risk factors by social
and behavioral determinants.
Obesity

Dysglycemia

Dyslipidemia

Hypertension Central obesity

MEN
Marital Status
Single/
29.1 (26.4-31.8)
divorced
Married 29.7 (26.4-32.9)
Employment Status
Un29.1 (23.5-34.6)
employed
Employed 29.8 (27.3-32.4)
Student 31.8 (26.3-37.3)
Education level
≤ high
32.7 (30.2-35.2)
school
≥ college 25.1 (22.6-27.7)
Family history of NCDs

14.1 (12.1-16.1) 68.3 (65.5-71.2) 33.8 (31-36.6) 27.8 (25.1-30.5)
15.8 (13.2-18.3)

67.5 (64-70.9) 28.6 (25.4-31.8) 30.8 (27.4-34.1)

17.8 (13.1-17.7) 68.2 (62.8-73.6) 30.8 (25.5-36.1) 27.0 (22.0-32.1)
15.7 (13.7-17.7) 68.2 (65.7-70.7) 33.6 (31.1-36.0) 36 (33.6-38.5)
9.4 (5.9-12.8) 69.8 (64.8-74.8) 26.2 (21.8-30.5) 18.6 (14.7-22.4)
15.7 (13.8-17.6)

68.6 (66-71.2) 33.7 (31.2-36.3) 30.6 (28-33.1)

13.7(11.7-15.6)

67.1 (64.3-70) 28.6 (25.9-31.2) 27.8 (25.1-30.5)

No
27.1 (24.7-29.6) 12.1(10.5-13.8) 65.7 (63.2-68.3) 25.7 (23.3-28.1) 29.3 (26.7-31.9)
Yes
31.8 (29.5-34.1) 15.6 (13.9-17.4) 69.7 (67.4-72) 35.1 (32.8-37.4) 29.8 (27.5-32.1)
Smoking
Non27.4 (24.7-30)
15.1(13-17.2) 63.6 (60.7-66.5) 32.7 (30-35.5) 26.4 (23.7-29.1)
smoking
Smoking 31.2 (28.5-33.9) 14.4(12.4-16.4) 71.1 (68.5-73.8) 31(28.3-33.6) 31.9 (29.2-34.7)
Physical Activity
Moderate/
25.2 (20-30.5)
11 (7.3-14.6)
66.8 (61-72.6) 33.1 (27.5-38.8) 22.9 (17.7-28)
high
Low PA 27.9 (25.2-30.6)
12 (10.1-14)
66.3 (63.4-69.2) 30.8 (28.1-33.6) 28.3 (25.5-31.1)
Data is presented as percentages (95% CI). Values in bold font have significant difference in
proportions of cardiometabolic risk factors.
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Table 6: Age-adjusted prevalence (95% CI) of cardiometabolic risk factors by social
and behavioral determinants. (Continued)
Obesity

Dysglycemia

Dyslipidemia

Hypertension

Central obesity

WOMEN
Marital Status
Single/
20.7 (18.5-23)
divorced
Married
22.3 (17.5-27)
Employment Status
Unemploy
24.5 (19.8-29.1)
ed
Employed 23.9 (19.2–28.5)
Student
17.7 (14-21.3)
Education level
≤ high
25.9 (22.7-29)
school
≥ college 15.8 (13.1-18.4)
Family history of NCDs

7.6 (6.1-9)

53.4 (50.6-56.2)

9.8 (8.1-11.4) 12.1 (10.2–13.9)

10.4 (7.1-13.8)

60.6 (54.6-66.6)

9 (5.9-12.1)

12.6 (9-16.1)

11.3 (8 – 14.7)

61.6 (56.4-66.8)

44.5 (8.1-15)

14.2 (10.5-17.9)

10.1 (6.9 – 13.3)
4.8 (2.8 – 6.7)

51.9 (46.3-57.6)
53.6 (48.9-58.3)

9.8 (6.6-12.9)
10 (7-12.9)

13.2 (9.6-16.8)
10.6 (7.5-13.6)

9.4 (7.4 – 11.5)

59 (55.6-62.4)

10.5 (8.4-12.7) 14.3 (11.8-16.8)

6.7 (4.9-8.4)

50 (46.4-53.7)

8.8 (6.8-10.9)

10.2 (8.1-12.3)

No
18.2 (15.34-21)
6.6 (4.8-8.3)
50.3 (46.7-53.9)
7 (5.1-8.8)
11.3 (9 – 13.7)
Yes
24.2 (21.6–26.7)
9.4 (7.7-11.1)
57.2 (54.3-60.1) 10.9 (9 – 12.8) 13.2 (11.1-15.2)
Smoking
Non20.2 (18.1-22.4)
7.6 (6.2-9)
54.2 (51.6-56.8) 9.5 (7.9-11.1)
11.3 (9.6-13)
smoking
Smoking 28.9 (18.9-38.9)
10.7 (4.3-17.2)
57.3 (46.3-68.3) 14 (6.5-21.5) 13.9 (6.6-21.2)
Physical Activity
Moderate/
21.9 (15.5-28.3)
9 (4.7-13.4)
58.4 (50.9-65.8) 10.7 (5.9-15.5) 7.7 (3.7-11.8)
High
Low PA
19.3 (16.5-22.2)
6.5(4.7-8.3)
52.4 (48.8-55.9) 9.5 (7.4-11.7) 10.2 (7.9-12.4)
Data is presented as percentages (95% CI). Values in bold font have significant difference in
proportions of cardiometabolic risk factors.

In men, obesity was found significantly higher in participants who were married,
students, and smokers. Having an abnormal glycemic status was more significantly
prominent in the married and unemployed groups. Moreover, dyslipidemia was higher
in the unmarried, students, and with lower education. Hypertension and central obesity
were significantly higher in the employed groups (Table 6).
In women, all cardiometabolic risk factors were higher in the married subjects,
with the exception of hypertension, where it was slightly higher in the unmarried.
Additionally, all risk factors were observed higher in the unemployed group. Only
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obesity was found significantly higher in terms of higher education and smoking
status. All cardiometabolic risk factors were higher in subjects with family history of
metabolic abnormalities, compared with no family history.
Figures 10 and 11 present grid illustrations for comorbid statuses of having two
cardiometabolic risk factors by gender and age groups, respectively. Among the people
with dyslipidemia, more than 70% had a concurrent metabolic condition. The
following condition was obesity, where 50% or more also had dyslipidemia or central
obesity. However, among subjects with abnormal glycemic status, 25% and below had
comorbidity with other risk factors. The patterns were similar in the whole sample,
between sexes and across age groups.
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Figure 10: Coexistence of cardiometabolic risk factors.
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Figure 11: Coexistence of cardiometabolic risk factors by age groups.

The five metabolic risk factors were then tested for associations with social and
behavioral determinants. In the overall study population, smokers had an almost 51%
(OR 1.51 (1.18 – 1.92)) increase in the odds of having dyslipidemia and 31% (OR 1.31
(1.01 – 1.70)) increase in the odds of having central obesity compared to nonsmokers.
Having a lower educational attainment was associated with an increased odd by 49%
(OR 1.49 (1.18-1.87)) for being obese. Being a student had a reduced odd ratio of 0.5
(0.29–0.87) for abnormal glycemia and an increased odd ratio of 1.41 (1.04–1.91) for
dyslipidemia, compared to being employed. Participants with a family history of
chronic disease had an increase of 40% to 70% in the odds of being obese (OR 1.39
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(1.08–1.79)) or hypertensive (OR 1.71 (1.3–2.26)), respectively, compared to people
without a family history.
Table 7 shows association between social and behavioral determinants and
having cardiometabolic risk factors by gender. In males, a significant association was
observed between smoking and dyslipidemia; 1.54 (1.18–2.0). Lower education
increased the odds of being obese by 43%; OR 1.43 (1.08–1.90). Being unemployed
had a lower odds ratio of 0.56 (0.35–0.90) for obesity and being a student had an odd
ratio of 0.44 (0.21–0.89) for dysglycemia. Family history increased the odds of having
hypertension by 66% (OR 1.66 (1.22–2.26)).
In females, significant associations were captured between smoking and
hypertension by almost 2.5-fold (OR 2.49 (1.10–5.60)). For the social elements, a
lower education level showed a significant relationship with obesity and dyslipidemia.
Family history increased the odds of having hypertension by more than 2-fold, OR
2.09 (1.07–4.09).
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Table 7: Odd ratios of the associations between social and behavioral determinants and
having cardiometabolic risk factors.
Obesity

Dysglycemia

Dyslipidemia

Hypertension

Central obesity

MEN
Marital Status
Married
ref
Unmarried
1.06 (0.73-1.54)
Employment Status
Employed
ref
Unemployed
0.56 (0.35-0.90)
Student
0.89 (0.58-1.38)
Education level
High education
ref
Lower education 1.43 (1.08-1.90)
Family history of NCDs
No
ref
Yes
1.34 (0.98-1.83)
Smoking
Non-smoking
ref
Smoking
1.04 (0.79-1.37)
Physical Activity
Moderate/High
ref
Low PA
1.30 (0.92-1.84)

ref
1.11 (0.68-1.81)

ref
1.14 (0.79-1.65)

ref
1.25 (0.87-1.80)

ref
0.80 (0.55-1.17)

ref
0.83 (0.46-1.52)
0.44 (0.21-0.89)

ref
1.02 (0.68-1.52)
1.33 (0.89-1.99)

ref
0.76 (0.5-1.17)
0.70 (0.46-1.07)

ref
1.05 (0.70-1.66)
0.95 (0.59 -1.52)

ref
1.06 (0.73-1.55)

ref
1.05 (0.80-1.39)

ref
1.23 (0.94-1.62)

ref
1.11 (0.84-1.48)

ref
1.13 (0.74-1.73)

ref
1.26 (0.95-1.67)

ref
1.66 (1.22-2.26)

ref
0.90 (0.68-1.26)

ref
0.88 (0.61-1.27)

ref
1.54 (1.18-2.0)

ref
0.84 (0.64-1.10)

ref
1.30 (0.99-1.71)

ref
ref
1.30 (0.79-2.12) 1.03 (0.74-1.43)
WOMEN

ref
0.96 (0.69-1.34)

ref
1.40 (0.98-2.02)

Marital Status
Married
ref
ref
ref
ref
ref
Unmarried
0.99 (0.61-1.61) 0.7 0 (0.35-1.40) 0.80 (0.52-1.23) 1.03 (0.56-1.89)
1.01 (0.57-1.81)
Employment Status
Employed
ref
ref
ref
ref
ref
Unemployed
1.1 (0.66-1.85) 1.15 (0.56-2.36) 1.44 (0.91-2.29) 1.41 (0.74-2.70)
0.92 (0.49-1.80)
Student
0.92 (0.5-1.67) 0.72 (0.28-1.84) 1.40 (0.86-2.29) 1.17 (0.53-2.60)
1.09 (0.60-1.77)
Education level
High education
ref
ref
ref
ref
ref
Lower education 1.69 (1.13-2.52) 1.81 (0.98-3.34) 1.40 (1.02-1.92) 1.09 (0.65-1.82)
1.19 (0.71-2.0)
Family history of NCDs
No
ref
ref
ref
ref
ref
Yes
1.53 (0.97-2.41) 2.09 (0.92-4.78) 1.17 (0.84-1.62) 2.09 (1.07-4.09)
1.28 (0.70-2.35)
Smoking
Non-smoking
ref
ref
ref
ref
ref
Smoking
1.54 (0.75-3.15) 2.02 (0.78-5.22) 1.27 (0.66-2.42) 2.49 (1.10-5.60)
1.49 (0.62-3.5)
Physical Activity
Moderate/High
ref
ref
ref
ref
ref
Low PA
0.95 (0.59-1.53) 0.69 (0.35-1.37) 0.74 (0.52-1.11) 1.02 (0.54-1.93)
1.71 (0.84-3.5)
Data is presented here as odd ratios (CI). Estimated values are derived from a multivariate adjustment
for age, gender, smoking, low physical activity, education, marital status, employment and family
history,

Table 8 presents the associations between the five cardiometabolic risk factors
adjusting only for age and gender. Since smoking, educational level and family history
showed significant associations with some metabolic risk factors, they were included
in the multivariate models presented in Table 9.
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Table 8: Odd ratios of the associations between the cardiometabolic risk factors
adjusted for age and sex.
Total population
Dysglycemia

2.98 (2.49-3.55)

Dyslipidemia

2.71 (2.32-3.15) 1.85 (1.51-2.26)

Hypertension

3.03 (2.61-3.52) 2.32 (1.92-2.79) 1.81 (1.54-2.12)

Central obesity

4.70 (4.04-5.46)

1.57 (1.29-1.9)

2.18 (1.85-2.56)

1.85 (1.58-2.17)

Obesity

Dysglycemia

Dyslipidemia

Hypertension

MEN
Dysglycemia

2.54 (2.06-3.14)

Dyslipidemia

2.38 (1.96-2.89) 1.55 (1.22-1.97)

Hypertension

3.19 (2.69-3.77) 2.18 (1.78-2.68)

Central obesity

4.72 (3.95-5.65) 1.29 (1.03-1.61) 2.10 (1.73-2.55) 1.77 (1.49-2.11)
Obesity

Dysglycemia

1.67 (1.4-2.0)
Dyslipidemia

Hypertension

WOMEN
Dysglycemia

2.54 (2.06-3.14)

Dyslipidemia

2.38 (1.96-2.89) 1.55 (1.22-1.97)

Hypertension
Central obesity

3.19 (2.69-3.77) 2.18 (1.78-2.68)
4.72 (3.95-5.65) 1.29 (1.03-1.61)
Obesity
Dysglycemia

1.67 (1.40-2.0)
2.10 (1.73-2.55)
Dyslipidemia

1.77 (1.49-2.11)
Hypertension

Data is presented as odds ratios (95% CI). Multivariate models adjusted for age and gender
only. For each risk factor, the reference groups were those without that risk factor.

All associations were found significant, however, when the model was adjusted
for all risk factors including smoking, education and family history, the associations
were attenuated, but remained significant with the exception of central obesity with
dysglycemia in both men and women, and with dyslipidemia in females, Table 9. The
strongest relationship was captured with obesity. For instance, obesity was associated
with 4-fold increase in the odds of having central obesity (OR 4.21 (3.5 – 5.06)), and
over 2-fold increase odds of having abnormal glycemic status (2.59 (2.06 – 3.24)),
hypertension (OR (2.35 (1.95–2.84)), and dyslipidemia (OR 2.08 (2.06 – 3.24)).

57
Table 9: Odd ratios of the associations between different cardiometabolic risk factors
adjusted for age, sex and each other.
TOTAL POPULATION
Dysglycemia

2.59 (2.06-3.24)

Dyslipidemia

2.08 (1.72-2.52) 1.56 (1.22-1.99)

Hypertension

2.35 (1.95-2.84) 1.92 (1.54-2.39) 1.42 (1.17-1.71)

Central obesity

4.21 (3.50-5.06) 0.93 (0.74-1.18) 1.54 (1.26-1.88) 1.35 (1.11-1.64)
Obesity

Dysglycemia

Dyslipidemia

Hypertension

MEN
Dysglycemia
Dyslipidemia
Hypertension
Central obesity

2.25 (1.73-2.95)
1.92 (1.51-2.45) 1.38 (1.03-1.85)
2.61 (2.12-3.23) 1.92 (1.5-2.47) 1.35 (1.09-1.68)
4.27 (3.44-5.30) 0.86 (0.66-1.13) 1.56 (1.23-1.98) 1.23 (1.01-1.49)
Obesity
Dysglycemia
Dyslipidemia
Hypertension

WOMEN
Dysglycemia 3.51 (2.31-5.35)
Dyslipidemia 2.42 (1.77-3.30)

1.96 (1.24-3.11)

Hypertension 1.58 (1.05-2.37)
Central
4.21 (2.95-6.02)
obesity

2.11 (1.31-3.41)

1.89 (1.26-2.86)

1.33 (0.83-2.13)

1.39 (0.96-2.02)

1.65 (1.05-2.57)

Dysglycemia

Dyslipidemia

Hypertension

Obesity

Data is presented as odds ratios (CI). Multivariate adjustment for age, gender, obesity,
abnormal glycemic status, hypertension, dyslipidemia and central obesity, as well as
educational level, smoking status and family history.
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5.2 Objective 2: Describe the burden of cardiometabolic risk factors
The burden of cardiometabolic risk factors was measured as the number of risk
factors per subject. Quarter of the population (25.5%) had zero risk factors. The
remaining population had a range from 1 to 5 risk factors. The majority of the sample
had either 1 risk factor (34.2%) or 2 risk factors (20.5%) as displayed in Figure 12.
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Figure 12: Burden of cardiometabolic risk factors.
The distribution of number of risk factors in men and women is visualized in
Figure 13. Males in this sample had more risk factors than females; 81% of men had
at least one risk factor versus 64% of women. With the exception of having only one
risk factor, the proportions of men suffering from a burden of having two to five risk
factors were consistently higher than women in this study population.
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Figure 13: Burden of risk factors in men and women of the sample.

Figure 14 shows the distribution of the burden of the cardiometabolic risk
factors within age groups. It shows that in the older age groups, the proportion of
accumulated risk factors increases. This was similar for the whole population and in
men and women. Interestingly, men with five risk factors were all older than 20 years,
however, a proportion of women aged 18 to 20 years was already having a burden of
5 cardiometabolic risk factors.
The burden of the risk factors was dichotomized to “0-1 RFs” and “≥2 RFs”.
Sixty percent of the population had 0-1 risk factors. Men had a higher burden of risk
factors compared to women across all age groups. Figure 15 shows the proportions of
risk factors across age groups. As age increased, the proportion of people with ≥2 risk
factors increased.

60

%

The whole population
50
45
40
35
30
25
20
15
10
5
0
0

1

18-<20

2

20-<25

25-<30

3

4

5

30-<35

35-40

3

4

30-<35

35-40

Men
50
40

%

30
20
10
0
0

1

18-<20

2

20-<25

25-<30

5

Women
50
40

%

30
20
10
0
0

1

18-<20

2

20-<25

25-<30

3

4

30-<35

35-40

5

P value = 0.00

Figure 14: Burden of risk factors in different age groups.
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Figure 15: Burden of risk factors: age groups and gender

Univariate associations between social and behavioral determinants with
having ≥ 2 cardiometabolic risk factors as the outcome is presented in Table 10. Most
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factors were significantly associated with the outcome, except for low physical
activity. Whereas the adjusted multivariate model in Table 11 shows that only age,
educational level, and family history were significantly associated with the outcome
after adjustment for age and other factors. For every 1-year increase in age, there is a
10% increase in the odds of having ≥ 2 cardiometabolic risk factors (OR 1.1 (1.08 –
1.13)). Not being a college graduate increased the odds of having ≥ 2 cardiometabolic
risk factors by 37% (OR 1.37 (1.1 – 1.69)), while having a parent with NCD increased
the odds by 44% (OR 1.44 (1.14 – 1.81)).

Table 10: Unadjusted odd ratios of social and behavioral factors associated with
having ≥ 2 cardiometabolic risk factors.
All
OR (95% CI)

Men
OR (95% CI)

Women
OR (95% CI)

Age
1.11 (1.09 - 1.12)
1.1 (1.08 - 1.11)
1.1 (1.08 - 1.12)
Marital status
Married (Ref)
Single / divorced
0.38 (0.34 - 0.43)
0.47 (0.40 - 0.55) 0.38 (0.30 - 0.49)
Employment level
Employed (Ref)
Unemployed
0.58 (0.49 - 0.70)
0.57 (0.45 - 0.74) 0.87 (0.65 - 1.16)
Student
0.32 (0.27 - 0.38)
0.50 (0.40 - 0.62) 0.34 (0.26 - 0.45)
Education level
Bachelors & above
(Ref)
High school & below
1.03 (0.91 - 1.16)
0.89 (0.77 - 1.04) 1.26 (1.02 - 1.56)
Family history
No (Ref)
Yes
1.63 (1.45 - 1.83)
1.74 (1.51 - 2.01) 1.80 (1.46 - 2.2)
Smoking
Non-smoking (Ref)
Smoking
2.10 (1.83 - 2.40)
1.41 (1.20 - 1.65) 1.82 (1.15 - 2.89)
physical activity
Mod-high PA (Ref)
Low PA
1.12 (0.92 - 1.37)
1.21 (0.94 - 1.55) 1.05 (0.73 - 1.50)
Data is presented as unadjusted odds ratios (CI). Univariate analysis for each factor with
having ≥2 CRF as an outcome.

In men, only age and family history showed an association with having a
burden of 2 or more cardiometabolic risk factors. Odd ratio for age was 1.1 (1.06 –
1.13), and positive family history of NCD increased the odds by 37% (OR 1.37 (1.04
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– 1.8)). For women, age accounted for a 12% increase in the odds (OR 1.12 (1.08 –
1.17)). Having a lower educational level accounted for 61% increase in the odds (OR
1.61 (1.1 – 2.34)) and family history of NCD accounted for 64% increase (OR 1.64
(1.07 – 2.51)).

Table 11: Adjusted odd ratios of social and behavioral factors associated with having
≥ 2 cardiometabolic risk factors.
All
OR (95% CI)
1.1 (1.08 - 1.13)

Men
OR (95% CI)
1.1 (1.06 - 1.13)

Women
OR (95% CI)
1.12 (1.08 - 1.17)

Age:
Marital status
Married (Ref)
Single
0.97 (0.74 - 1.26)
1.07 (0.76 - 1.5)
0.83 (0.53 - 1.31)
Employment level
Employed (Ref)
Unemployed
1.05 (0.78 - 1.42)
0.79 (0.52 - 1.18)
1.41 (0.86 - 2.32)
Student
1.16 (0.84 - 1.59)
1.11 (0.75 - 1.64)
1.34 (0.76 - 2.38)
Education level
Bachelors & above
(Ref)
High school & below
1.37 (1.1 - 1.69)
1.28 (0.99 - 1.66)
1.61 (1.1 - 2.34)
Family history
No (Ref)
Yes
1.44 (1.14 - 1.81)
1.37 (1.04 - 1.8)
1.64 (1.07 - 2.51)
Smoking
Non-smoking (Ref)
Smoking
1.22 (0.97 - 1.54)
1.18 (0.92 - 1.52)
1.89 (0.97 - 3.68)
Physical activity
Mod-high PA (Ref)
Low PA
1.17 (0.90 - 1.52)
1.31 (0.95 - 1.79)
0.97 (0.62 - 1.52)
Data is presented as adjusted odds ratios (CI). Multivariate analysis for each factor with having
≥2 MRF as an outcome. Model is adjusted for age, gender as well as employment, education,
marital status, smoking, physical activity and family history.

5.3 Objective 3: Investigate the effect of BMI on the other cardiometabolic risk
factors and their burden
Around two-thirds of the population were either overweight (30.8%) or obese
(27.2%), as shown in Figure 16. Across genders, there were more men in the
overweight and obese categories than women, as shown in Figure 17.
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Figure 16: Body Mass Index classification of the study population.

Figure 17: Body Mass Index categories distribution in men and women.
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Figure 18: Distribution of BMI across age groups and sexes
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Linear regression models showed an odd ratio of 1.30 (1.26 – 1.34) for age as
an exposure variable and BMI as an outcome. Figure 18 shows that overweight and
obesity proportions increase significantly as age increases in the whole population, as
well as in each sex.
Tables 12 and 13 show the difference in the distribution of cardiometabolic
risk factors across the BMI classes and age groups in men and women; respectively.
The mean values for cardiometabolic markers change between BMI classes, this
change is also reflected when the measurement values are converted to categorical
definitions.
In both men and women, the proportion of those with an abnormal HbA1c
increased from 15% in the normal BMI group, to 24-27% in the overweight group,
and 57-60% in the obese group. Fasting glucose levels also increase as BMI increases.
The youngest age group had higher glycemia rates in the normal-BMI class than other
classes.
Lipid markers also differ across the BMI groups. Mean values for lipid markers
increase as BMI increases. In both men and women below 20 years, it was observed
that more glucose and lipid abnormalities within the normal BMI groups than
overweight and obese groups.
Blood pressure measurements, systolic blood pressure and diastolic blood
pressure increase significantly from normal, to overweight to obese classes. In men,
elevated blood pressure increases from 17.2% in the normal BMI, to 34.7% in the
overweight, to 48.1% in the obese group. In women, it increases from 28.3% to 27.8%
to 43.9% in the normal, overweight and obese groups, respectively.
Waist-to-hip ratios also significantly increase as BMI increases. Central
obesity increases in men from 13.2% to 32.2% to 54.6% from the normal BMI to the
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overweight and obese, respectively. The pattern is similar for women as well, as shown
in Table 13. After stratifying by age group, women in the young populations (age 18 < 25) had higher percentages of people with central obesity in the normal group than
in the overweight group observed. In men, this was seen only in the 18-20 age group.

68
Table 12: Cardiometabolic risk factors by BMI class and age groups in men.
BMI class
P-value
Normal
Overweight Obese
5.29 (0.69) 5.18 (0.64) 5.24 (0.55) 5.47 (0.85) 0.00
Total

HbA1c, %
Elevated HbA1c
All
270
18 - <20
14
20-<25
45
25-<30
60
30-<35
76
35-40
75
Fasting glucose mg/dL 96.5 (25.7)
Elevated FBG
All
185
18 - <20
17
20-<25
60
25-<30
62
30-<35
31
35-40
15
LDL mg/dL
121.6 (35.7)
Abnormal LDL
All
1,232
18 - <20
68
20-<25
329
25-<30
309
30-<35
303
35-40
223
HDL mg/dL
43.9 (10.5)
Abnormal HDL
All
1,331
18 - <20
125
20-<25
374
25-<30
321
30-<35
287
35-40
224
Cholesterol mg/dL
185.6 (38.6)
Abnormal total Cholesterol
All
1,120
18 - <20
44
20-<25
293
25-<30
281
30-<35
286
35-40
216
Continued next page

41 (15.2%)
5 (35.7%)
13 (28.9%)
8 (13.3%)
9 (11.8%)
6 (8%)
94.2 (26.2)

75 (27.8%)
1 (7.1%)
16 (35.6%)
14 (23.3%)
23 (30.0%)
21 (28%)
93.6 (9.8)

154 (57%)
8 (57.1%)
16 (35.6%)
38 (63.3%)
44 (57.9%)
48 (64%)
101.6 (32.7)

0.00
0.005
0.067
0.00
0.00
0.00
0.00

56 (30.3)
13 (76.5%)
16 (26.7%)
15 (24.2%)
11 (35.5%)
1 (6.7%)
110.7(33.5)

50 (27%)
2 (11.8%)
19 (31.7%)
16 (25.8%)
11 (35.5%)
2 (13.3%)
125.3 (34.4)

79 (42.7%)
2 (11.8%)
25 (41.7%)
31 (50%)
9 (29%)
12 (80%)
129.8 (36.5)

0.001
0.170
0.005
0.039
0.856
0.158
0.00

275(22.3%)
29 (42.7%)
100(30.4%)
69 (22.3%)
45 (14.9%)
32 (14.4%)
47.1 (10.6)

475 (38.6%)
18 (26.5%)
110 (33.4%)
118 (38.2%)
127 (41.9%)
102 (45.7%)
43.4 (10.8)

482 (39.1%)
21 (30.9%)
119 (36.2%)
122 (39.5%)
131 (43.2%)
89 (39.9%)
40.8 (9)

0.00
0.017
0.00
0.00
0.00
0.383
0.00

305(22.9%)
54 (43.2%)
118(31.6%)
64 (19.9%)
49 (17.1%)
20 (8.9%)
174.9(36.2)

486 (36.5%)
32 (25.6%)
123 (32.9%)
120 (37.4%)
115 (40.1%)
96 (42.9%)
189.9 (37.8)

540 (40.6%)
39 (31.2%)
133 (35.6%)
137 (42.7%)
123 (42.9%)
108 (48.2%)
192.9(39.5)

0.00
0.00
0.00
0.00
0.001
0.00
0.00

250 (22.3%)
17 (38.6%)
91 (31.1%)
65 (23.1%)
44 (15.4%)
33 (15.3%)

438 (39.1%)
10 (22.7%)
96 (32.8%)
105 (37.4%)
127 (44.4%)
100 (46.3%)

432 (38.6%)
17 (38.6%)
106 (36.2%)
111 (39.5%)
115 (40.2%)
83 (38.4%)

0.00
0.005
0.00
0.00
0.001
0.270
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Table 12: Cardiometabolic risk factors distribution by BMI class and age groups in
men (Continued)
BMI class
Normal
Overweight Obese
119.1 (85.7) 89.0 (65.0) 124.2 (84.4) 148 (96.6)
Total

P-value

Triglycerides mg/dL
0.00
Abnormal TG
All
513
214(41.7%) 131 (25.5%) 168 (32.8%) 0.00
18 - <20
45
19 (42.2%) 9 (20%)
17 (37.8%) 0.010
20-<25
194
45 (23.2%) 70 (36.1%) 79 (40.7%) 0.00
25-<30
205
32 (15.6%) 78 (38.1%) 95 (46.3%) 0.00
30-<35
220
29 (13.2%) 92 (41.8%) 99 (45%)
0.00
35-40
185
13 (7%)
75 (40.5%) 97 (52.4%) 0.00
Systolic BP, mmHg 131.2 (13.1) 125 (11.4) 132 (12.1) 137.5 (12.6) 0.00
Diastolic BP, mmHg 80.3 (10.2) 76.6 (8.9) 80.3 (9.9) 84.7 (10.3) 0.00
Elevated blood
pressure
All
902
155 (17.2%) 313 (34.7%) 434 (48.1%) 0.00
18 - <20
78
27 (34.6%) 20 (25.6%) 31 (39.7%) 0.00
20-<25
278
62 (22.3%) 108 (38.9%) 108 (38.9%) 0.00
25-<30
233
36 (15.5%) 78 (33.5%) 119 (51.1%) 0.00
30-<35
175
21 (12%)
59 (33.7%) 95 (54.3%) 0.00
35-40
138
9 (6.5%)
48 (34.8%) 81 (58.7%) 0.00
Waist-Hip Ratio
0.87 (0.07) 0.83 (0.07) 0.87 (0.7) 0.91 (0.06) 0.00
Central obesity
All
895
118 (13.2%) 288 (32.2%) 489 (54.6%) 0.00
18 - <20
41
8 (19.5%) 7 (17.1%) 26 (63.4%) 0.00
20-<25
214
39 (18.2%) 56 (26.2%) 119 (55.6%) 0.00
25-<30
214
27 (12.6%) 71 (33.2%) 116 (54.2%) 0.00
30-<35
232
26 (11.2%) 81 (34.9%) 125 (53.9%) 0.00
35-40
194
18 (9.3%) 73 (37.6%) 103 (53.1%) 0.00
Data is presented here as means (standard deviations) or N (%). P values are derived
from ANOVA, chi-square tests and Fisher-exact tests. Elevated blood pressure is
based on systolic and diastolic blood pressure, as well as, self-report and use of
medication.
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Table 13: Cardiometabolic risk factors by BMI class and age groups in women.
BMI class
Overweight Obese
5.23 (0.50) 5.45 (0.78)

P-value

20 (15.5%)
11 (47.8%)
4 (17.4%)
3 (13.6%)
0
2 (5.1%)
84.2 (7.7)

31 (24%)
5 (21.7%)
5 (21.7%)
3 (13.6%)
6 (27.3%)
12 (30.8%)
91.9 (23)

78 (60.5%)
7 (30.4%)
14 (60.9%)
16 (72.7%)
16 (72.7%)
25 (64.1%)
95.6 (37.1)

0.00
0.117
0.00
0.00
0.00
0.002
0.00

5 (16.1%)
2 (66.7%)
0
3 (42.9%)
0
0
99.7 (25.3)

14 (45.2%)
0
3 (42.9%)
2 (28.6%)
3 (75%)
6 (60%)
108.6 (28.3)

12 (38.7%)
1 (33.3%)
4 (57.1%)
2 (28.6%)
1 (25%)
4 (40%)
118.3 (29.9)

0.00
0.412
0.005
0.811
0.053
0.182
0.00

160 (35.2%)
44 (54.3%)
60 (45.5%)
24 (29.6%)
15 (24.2%)
17 (17.4%)
58.9 (12.4)

123 (27.1%)
13 (16.1%)
30 (22.7%)
24 (29.6%)
22 (35.5%)
34 (34.7%)
54.8 (13)

171 (37.7%)
24 (29.6%)
42 (31.8%)
33 (40.7%)
25 (40.3%)
47 (48%)
49.5 (11.8)

0.00
0.001
0.00
0.001
0.053
0.129
0.00

289 (37.4%)
87 (47.3%)
125 (48.8%)
35 (27.1%)
25 (27.2%)
17 (15.2%)
172.7(28.1)

204 (26.4%)
43 (23.4%)
61 (23.8%)
32 (24.8%)
33(35.9%)
35 (31.3%)
179.6 (31.2)

280 (36.2%)
54 (29.4%)
70 (27.3%)
62 (48.1%)
34 (37%)
60 (53.6%)
185.1 (32.7)

0.00
0.00
0.00
0.00
0.067
0.00
0.00

214 (41.7%)
52 (58.4%)
80 (54.4%)
34 (39.1%)
23 (28.1%)
25 (23.2%)

131 (25.5%)
15 (16.9%)
26 (17.7%)
22 (25.3%)
31 (37.8%)
37 (34.3%)

168 (32.8%)
22 (24.7%)
41 (27.9%)
31 (35.6%)
28 (34.2%)
46 (42.6%)

0.00
0.046
0.00
0.177
0.217
0.923

Total
Normal
5.215 (0.58) 5.11 (0.48)

HbA1c, %
Elevated HbA1c
All
129
18 - <20
23
20-<25
23
25-<30
22
30-<35
22
35-40
39
Fasting glucose mg/dL 88.8 (22.3)
Elevated FBG
All
31
18 - <20
3
20-<25
7
25-<30
7
30-<35
4
35-40
10
LDL mg/dL
106.0(28.13)
Abnormal LDL
All
454
18 - <20
81
20-<25
132
25-<30
81
30-<35
62
35-40
98
HDL mg/dL
55.8 (13)
Abnormal HDL
All
773
18 - <20
184
20-<25
256
25-<30
129
30-<35
92
35-40
112
Cholesterol mg/dL
177.1 (30.3)
Abnormal total Cholesterol
All
513
18 - <20
89
20-<25
147
25-<30
87
30-<35
82
35-40
108
Continued next page

0.00
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Table 13: Cardiometabolic risk factors by BMI class and age groups in women.
(Continued)

79.3 (52.8)

Normal
64.7 (36.9)

BMI class
P-value
Overweight Obese
85.1 (57.8) 108.2 (65.4) 0.00

281
50
65
50
49
67
117.8 (11.5)
74.3 (9.3)

86 (30.6%)
26 (50%)
25 (38.5%)
16 (32%)
10 (20.4%)
9 (13.4%)
113.4 (9.7)
72 (7.5)

76 (27.1%)
8 (16%)
17 (26.2%)
12 (24%)
18 (36.7%)
21 (31.3%)
119.5(10.2)
75.5 (8.6)

119 (42.4%)
16 (32%)
23 (35.4%)
22 (44%)
21 (42.9%)
37 (55.2%)
126 (11.7)
78.5 (9.3)

0.00
0.005
0.00
0.033
0.026
0.014
0.00
0.00

180
33
42
35
24
46
0.77 (0.08)

51 (28.3%)
15 (45.5%)
20 (47.6%)
7 (20%)
3 (12.5%)
6 (13%)
0.74 (0.07)

50 (27.8%)
8 (24.2%)
8 (19.1%)
7 (20%)
10 (41.7%)
17 (37%)
0.77 (0.07)

79 (43.9%)
10 (30.3%)
14 (33.3%)
21 (60%)
11 (45.8%)
23 (50%)
0.81 (0.08)

0.00
0.033
0.010
0.00
0.031
0.139
0.00

258
43
59
44
44
68

54 (20.9%)
13 (30.2%)
18 (30.5%)
7 (15.9%)
6 (13.6%)
10 (14.7%)

60 (23.3%)
9 (20.9%)
8 (16.6%)
10 (22.7%)
13 (29.6%)
20 (29.4%)

144 (55.8%)
21 (48.8%)
33 (55.9%)
27 (61.4%)
25 (56.8%)
38 (55.9%)

0.00
0.00
0.00
0.00
0.00
0.007

Total
Triglycerides mg/dL
Abnormal TG
All
18 - <20
20-<25
25-<30
30-<35
35-40
Systolic BP, mmHg
Diastolic BP, mmHg
Elevated blood pressure
All
18 - <20
20-<25
25-<30
30-<35
35-40
Waist-Hip Ratio
Central obesity
All
18 - <20
20-<25
25-<30
30-<35
35-40

Data is presented here as means (standard deviations) or N (%). P values are derived
from ANOVA, chi-square tests and Fisher-exact tests. Elevated blood pressure is
based on systolic and diastolic blood pressure, as well as, self-report and use of
medication.
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Tables 14 and 15 present the unadjusted and age-adjusted prevalence rates for
each metabolic risk factor by BMI class, in men and women, respectively. The
prevalence of all risk factors significantly increase as the BMI increases. Obesity had
the highest prevalence rates of cardiometabolic risk factors in men and women; this is
visualized in Figure 19. In the overall sample, among the obese, 51.7% had
dysglycemia, 35.1% had dyslipidemia, 47.4% were hypertensive and 55% had central
obesity. The trends were similar in men and women.
Table 14: Unadjusted and age-adjusted prevalence of cardiometabolic risk factors by
BMI class in Men.
Total
% (95% CI)
Elevated HbA1c
Unadjusted
9.35 (8.4-10.4)
Age-adjusted
8.1 (7.1-9.1)
Abnormal FBG
Unadjusted
24.4 (21.4-27.5)
Age-adjusted
24.1 (21.0-27.1)
Abnormal LDL
Unadjusted
42.5 (40.8-44.2)
Age-adjusted
42.1 (40.3-43.9)
Abnormal HDL
Unadjusted
45.5 (43.7-47.2)
Age-adjusted
45.4 (43.6-47.1)
Abnormal total Cholesterol
Unadjusted
38.0 (36.3-39.7)
Age-adjusted
37.2 (35.4-38.9)
Abnormal TG
Unadjusted
28.2 (26.6-29.7)
Age-adjusted
26.7 (25.1-28.3)
Elevated BP
Unadjusted
27.9 (26.3-29.5)
Age-adjusted
27.7 (26.1-29.3)
Central obesity
Unadjusted
30.9 (29.3-32.6)
Age-adjusted
29.6 (27.9-31.3)

Normal
% (95% CI)
4.0 (2.8-5.2)
4.4 (3.1-5.7)

Overweight
% (95% CI)
7.4 (5.8-9.0)
6.0 (4.6-7.4)

Obese
% (95% CI)
17.5 (15.0-20.1)
14.6 (12.2-17.0)

18.4 (14.0-22.7)
19.0 (14.5-23.5)

23.8 (18.0-29.6) 32.4 (26.5-38.2)
23.2 (17.5-28.9) 30.9 (25-36.8)

27.0 (24.3-29.8)
29.9 (26.9-32.9)

46.6 (43.5-49.6) 54.8 (51.5-58.1)
44.4 (41.2-47.5) 52.5 (49.1-55.9)

30.0 (27.2-32.8)
31.7 (28.8-34.7)

47.6 (44.6-50.7) 61.3 (58.1-64.5)
46.5 (43.4-49.6) 60.2 (56.9-63.5)

24.6 (21.9-27.2)
27.4 (24.5-30.4)

42.9 (40.0-46.0) 49.0 (45.7-52.3)
40.2 (37.1-43.3) 46.1 (42.6-49.5)

13.6 (11.5-15.7)
14.0 (12.7-17.3)

31.8 (29.0-34.7) 44.0 (40.7-47.3)
29.1 (26.2-32.0) 41.0 (37.6-44.3)

13.1 (11.1-15.2)
13.3 (11.2-15.5)

27.5 (24.7-30.2) 45.3 (42.0-48.6)
27.3 (24.5-30.1) 45.0 (41.7-48.3)

11.6 (9.6-13.5)
12.7 (10.6-14.9)

28.9 (26.0-31.7) 56.1 (52.8-59.4)
25.9 (23.1-28.7) 53.6 (50.2-57.1)

73
Table 15: Unadjusted and age-adjusted prevalence of cardiometabolic risk factors by
BMI class in Women.
Total
% (95% CI)
Elevated HbA1c
Unadjusted
6.9 (5.8-8.1)
Age-adjusted
5.9 (4.8-7.0)
Abnormal FBG
Unadjusted
10.5 (7.0-14.0)
Age-adjusted
9.1 (5.6-12.5)
Abnormal LDL
Unadjusted
23.9 (22.0-25.8)
Age-adjusted
22.9 (20.9-24.8)
Abnormal HDL
Unadjusted
41.2 (39.0-43.4)
Age-adjusted
41.1 (38.9-43.3)
Abnormal total Cholesterol
Unadjusted
27.0 (25.1-29.0)
Age-adjusted
26.0 (24.0-28.0)
Abnormal TG
Unadjusted
14.8 (13.2-16.3)
Age-adjusted
13.5 (11.9-15.1)
Elevated BP
Unadjusted
5.9 (4.8-7.0)
Age-adjusted
5.2 (4.1-6.3)
Central obesity
Unadjusted
13.9 (12.3-15.4)
Age-adjusted
12.5 (10.9-14)

Normal
% (95% CI)

Overweight
% (95% CI)

Obese
% (95% CI)

2.0 (1.1-2.8)
2.1 (1.2-3.0)

7.1 (4.7-9.5)
5.9 (3.7-8.0)

18.4 (14.7-22.1)
15.1 (11.6-18.7)

3.4 (0.5-6.3)
3.6 (0.5-6.7)

19.2 (10.1-28.2)
16.3 (7.6-25)

17.6 (8.6-26.7)
14.7 (6.3-23.2)

15.8 (13.5-18.1)
16.8 (14.4-19.1)

27.8 (23.7-32.1) 40.1 (35.5-44.8)
25.4 (21.3-29.5) 36.3 (31.6-41.1)

28.5 (25.7-31.2)
28.7 (25.9-31.6)

46.2 (41.5-50.8) 65.7 (61.2-70.2)
45.9 (41.2-50.6) 65.3 (60.7-69.9)

21.1 (18.6-23.6)
22.7 (20-25.4)

29.6 (25.4-33.9) 39.4 (34.8-44.1)
26.3 (22.1-30.5) 34.6 (29.9-39.2)

8.5 (6.8-10.2)
9.0 (7.2-10.8)

17.2 (13.7-20.7) 27.9 (23.7-32.2)
14.8 (11.5-18.1) 23.8 (19.6-28.0)

1.8 (1.0-2.7)
1.9 (1.0-2.8)
5.5 (4.0-6.9)
5.8 (4.3-7.3)

6.5 (4.1-8.8)
5.6 (3.5-7.8)

14.5 (11.1-17.8)
12.3 (9.0-15.5)

13.8 (10.6-17.1) 34 (29.5-38.6)
11.9 (8.9-14.9) 30.1 (25.5-34.6)
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P value= 0.0

Figure 19: Distribution of cardiometabolic risk factors across BMI groups and
Gender.
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Figure 20 shows as BMI increases people tend to accumulate more risk factors.
Grouping the 4 remaining metabolic risk factors; dysglycemia, dyslipidemia,
hypertension and central obesity, into 2 groups; 0-1 Risk factors and 2-4 Risk factors,
allowed to show the difference in the burden based on BMI classes. Figure 21 shows
the burden of risk factors similarly increases as the BMI increases, in the whole
population, as well as, in each sex. Thirteen percent of the normal-BMI population had
an accumulation of 2 or more risk factors, 37% in the overweight and 63% in the obese.
In men, interestingly 20% of those with normal BMI already had two or more other
cardiometabolic risk factors, and the proportion increased to 71.4% in the obese group.
Only forty-five percent of obese women had an accumulation of 2-4 metabolic risk
factors.

P value= 0.00

Figure 20: Number of accumulated cardiometabolic risk factors distribution by BMI
status.
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P value= 0.00

Figure 21: Burden of cardiometabolic risk factors by BMI status and Gender.
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In unadjusted univariate logistic model, almost all social and behavioral
determinants were significantly associated with accumulating of 2-4 cardiometabolic
risk factors across BMI classes. However, in the forward-stepwise approach, it was
shown that only age was significantly associated with the increased burden of
cardiometabolic risk factors (Table 16). In men, age increased the odds of having 2-4
risk factors by 9% (OR 1.09 (1.05 – 1.15)) in the normal BMI group, and by 7% (OR
1.07 (1.03 – 1.11)) in the overweight. In women, age had a similar effect to that in
men, where it increased the odds by 8 – 10% across the BMI classes; 1.08 (1.01 – 1.15)
in the normal BMI, 1.10 (1.04 – 1.16) in the overweight and 1.08 (1.03 – 1.13) in the
obese. Additionally, the effect of being employed showed a significant increase in the
odds of having 2-4 risk factors in obese men only.
Table 16: Forward-stepwise association of having ≥2 cardiometabolic risk factors in
BMI classes in men and women.

Men
Age
Employment
Women
Age

Normal
Adjusted OR (95%
CI)

BMI Classification
Overweight
Adjusted OR (95%
CI)

1.09 (1.05 - 1.15)

1.07 (1.03 - 1.11)

Obese
Adjusted OR (95%
CI)
2.54 (1.5 – 4.3)

1.08 (1.01 - 1.15)

1.10 (1.04 - 1.16)

1.08 (1.03 - 1.13)

Data is presented as Odd ratio (95% confidence interval). Gender reference group is
males. Employment status reference group is being unemployed.
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Chapter 6: Discussion
This thesis presents the first local comprehensive epidemiological description
of the major cardiometabolic risk factors: obesity, dysglycemia, dyslipidemia,
hypertension and central obesity, based on a large sample of young Emirati population.
The thesis addressed the inter-relationship between the cardiometabolic risk factors
and their clustering distribution. Furthermore, for the first time, it presents the effect
of social factors, family history of NCDs and behavioral determinants on the
prevalence of the cardiometabolic risk factors and their burden, and assesses the
associations between these determinants and the cardiometabolic risk factors.
Moreover, the study shows how the cardiometabolic risk factors are distributed across
different BMI classes and how they are affected by other variables.
6.1 Objective 1: Describe the distribution of cardiometabolic risk factors in the
population.
Obesity was present in 27.2% of the population. The age-adjusted prevalence
rate was 26.5% (25.2 – 27.7). This rate was similar to prevalence rates reported locally,
where the rates of obesity ranged from 25% to 35.4% in similar age groups (11, 17,
37, 81). In this study, obesity was higher in men than in women; 29.7% and 21.6%,
respectively. This trend was similar to another nation-wide study published in 2012
(17). Moreover, obesity significantly increased with increasing age, in the whole study
population and in each sex. The previous national survey showed similar trends across
age groups (11). The age-standardized rate of obesity of 30% is quite alarming
compared to that of the global rate of 12% (156).
The age-adjusted prevalence rates for diabetes was 3.5%, and for pre-diabetes
rate was 8.2% in the whole study population. These rates were similar to the ones
reported by the UAE national survey for the age group 18-44; diabetes had a
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prevalence of 3.3% and prediabetes was 6.5% among Emiratis (11). The study findings
showed that the age-adjusted prevalence of dysglycemia in this population was 11.7%
and it was higher in males (14%) than in females (8.3%). Similarly, as shown with
other cardiometabolic risk factors, the proportion of people with abnormal glycaemia
increases with age. In this analysis, the rates of glycaemia doubled from the youngest
age group (below 20 years) to the oldest age group (35 to 40 years). It was found that
7.6% of participants aged 18 and 19, and 8.3% of participants between 20 and 24 years
had abnormal glycemic status. This supports the international connotation that
prediabetes and diabetes are rapidly rising in the adolescents and young adults as
reported by the Centre for Disease Control and Prevention (CDC) (59). Rates in UAE
are very high; according to the IDF, the age-adjusted prevalence of diabetes was 16.3%
in UAE, while it is 12.2% in the Middle East and North Africa (MENA) region in 2019
(61). The MENA region had the highest rate compared to other parts of the globe. A
recent local analysis on 33,000 men revealed a relatively higher prediabetes prevalence
of 33% in the 18-19 age group, and 40.2% in the 20-24 age group (37) based on fasting
blood glucose measurements.
The differences in the methodological approaches could explain the difference
prevalence of prediabetes reported in this thesis as only 20.8% of this population had
fasting blood sample and therefore HbA1c was mainly used as a marker for diabetes
and prediabetes. HbA1c is a validated and trusted tool to be used for diabetes
classification (152). However, it raises some concerns when used to diagnose for
prediabetes (157). Validation studies on HbA1c, for prediabetes, had been assessed
against oral glucose tolerance test (OGTT) internationally. Depending on the defining
criteria, HbA1c may capture only 50% of abnormal OGTT. Glycated hemoglobin is
affected by ethnic, racial and gender differences. Although it has shown to
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underestimate for prediabetes, its sensitivity and specificity still appears to be useful,
convenient and reliable for both screening and diagnostic purposes (158, 159).
With the broad definition of dyslipidemia applied in this project, the results
revealed that 61.7% of the whole population as having an abnormality in their lipid
profiles. This high proportion of dyslipidemia might not be comparable to other local
studies due to the difference in the definition criteria and methods of blood sampling;
fasting or random (17, 37). Although, blood collection for lipid testing purposes are
traditionally required to be fasting samples, dyslipidemia analyses were done using
non-fasting blood samples in this study population. Recent reports show that random
blood samples are acceptable (160, 161). Moreover, observational studies demonstrate
that in comparison to fasting level, measurements only altered minimally, by 8 mg/dL
or-0.2 mmol/L, when compared to fasting lipid levels. Nevertheless, when applying
the Weqaya’s definition of dyslipidemia in this sample population, dyslipidemia
would account for 43.2%, which is comparable to the Weqaya finding within the 1839 age group (17). Similarly, in another national report, abnormal total cholesterol
levels were comparable in the same age group (18-29) (37). The global prevalence of
dyslipidemia among adults was 39% in 2008 (82). This rate was found associated with
the income of the country. The rates were doubled in high-income countries compared
to low-income countries.
Elevated blood pressure was identified in 22.9% of the sample. It was shown
that hypertension in men was 3-folds higher than in women, 30.9% versus 9.2%,
respectively. Interestingly in men, hypertension was highest (30%) in the 20-24 age
group, whereas in women, the rate was highest (25%) in the oldest age group; 35 – 40
years. These rates were comparable with other national studies for similar age groups.
In all reports, men consistently had higher prevalence rate for hypertension than
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women (11, 17). The Coronary Artery Risk Development in Young Adults (CARDIA)
study in the US showed a similar trend in young adults (162); hypertension prevalence
was 20% in the adults aged 18 to 30. A global prevalence of 26.4% was estimated
among adults in year 2000 (163). In the age and gender breakdown, hypertension was
reported in 12.7% among the 20-29 age group and 18.4% in the 30-39 age group in
men. Men had double the rates of women in all age groups.
The prevalence of abdominal obesity in this study population was estimated as
24.3%, and males had a higher rate than women; 29.6% and 12.5%, respectively.
However, these findings were lower than the Weqaya study, where the prevalence
rates for abdominal obesity were 46.5% in men and 36.4% in women, aged 18-39 years
(17). In a smaller local study on young women aged 18-25 years, high waist
circumference was detected in 18.2% of the sample (38). In the US, the NHANES
report of 2007-2010 estimated abdominal obesity in 18-39 age group as 38.7% (164).
It is well established that before heart disease or diabetes develops, multiple
metabolic abnormalities co-exist. The clustering of the cardiometabolic risk factors
showed interesting patterns in this study population. Dyslipidemia showed that it
coexisted with another metabolic abnormality in more than 75% of the time, followed
by obesity and central obesity. Hajat et al. presented that cardiometabolic comorbidity
was most evident in diabetic participants (17). Most metabolic diseases co-existed with
dyslipidemia, followed by obesity. The patterns were also similar across gender and
age groups. However, since males had higher prevalence of some metabolic markers
than females did, this was reflected in the comorbidity as well. Although the pattern
was similar in all 3 age groups, as illustrated in Figure 12, comorbidity became more
intense as age increased.
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Moreover, when investigating the associations in between the cardiometabolic
risk factors after the adjustment for each other, different associations between different
pairs of cardiometabolic risk factors indicate that these risk factors cluster differently
in people. Overall, obesity had the strongest relationship with all metabolic
abnormalities. Baynouna et al. (165) showed that the strongest interrelationship
between risk factors was detected with obesity; with hypertension, with an odd ratio
1.9 (1.2 – 3.0), and with high LDL, odd ratio 1.7 (1.1-2.5). To exclude collinearity
between obesity and central obesity, correlation tests between BMI and waist-to-hip
ratio were carried out. The estimated correlation was 0.42. Interestingly, among
individuals that did not have central obesity, 18.5% were BMI-obese. As for those that
did have central obesity, only 54% had BMI-obesity.
In men, the prevalence of obesity, dysglycemia and central obesity were higher
in the married individuals, and among smokers. Interestingly, male students were more
obese and with higher rate of lipid abnormalities than the employed and unemployed
individuals. People with less than an undergraduate degree showed a higher prevalence
of obesity and dyslipidemia. In women, being married or unemployed had higher
prevalence rates of most risk factors. Having a low education had higher obesity.
Among smokers, obesity was more prominent than non-smokers. For family history,
the risk factors were found higher in those that had a family history of noncommunicable diseases than those that did not have a family history in both men and
women. There was no significant difference in the distribution of risk factors according
to physical activity classes. This could be attributable to the low power, as only 45%
of the population had valid physical activity data.
The findings showed that having a lower education attainment had consistently
increased the odds of being obese. Similar to previous research, obesity was found to
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be associated with being employed. A study by Veronesi found an association between
employment and raised cardiometabolic risk factors (166). This association was
explained by work-related stress, spending long hours sitting, long hours and shift
work – all of these employment factors have been linked to increased obesity and other
cardiovascular risk factors. Dysglycemia was found to be associated only with
employment status in this analysis; being a student reduced the odds of having an
abnormal glycemic status by 50–66 percent. Dyslipidemia was associated with
smoking, being a student and having lower education. Central obesity was associated
with behavioral risk factors, smoking and physical inactivity. Only one local previous
study investigated the association of smoking with cardiometabolic risk factors (165),
and found that smoking was associated with low HDL, which supports the study
finding. A prospective-analysis published in 2017 identified the patterns of clustering
of cardiovascular risk factors (167). It showed that low physical activity, lower
education and family history of CVD had higher risk factors accumulation in men.
6.2 Objective 2: Describe the burden of cardiometabolic risk factors.
Overall, one quarter of the total sample population had no cardiometabolic risk
factors. However, almost half (47.7%) of the male population in this study had two or
more risk factors, while only 28% of the female’s population did. Grouping the burden
into two categories, 0-1 and 2-5 risk factors yielded a 60-40 ratio; 60% had one or no
risk factor, and 40 had two or more risk factors. However, this should be considered
as alarming findings bearing in mind that this was a young population sample with age
range between 18-40. surprisingly, even 24% of the subjects in the youngest age
group18-19 years were already having 2 or more cardiometabolic risk factors.
A recent report from the UAE National Health Survey estimated that 49.5% of
the 18-44 years’ population have three or more of the following risk factors: smoking,
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inadequate diet, insufficient physical activity, overweight, or raised blood pressure
(11). The survey results indicated that there were more men than women with such
criteria (54.4% vs. 45.1% respectively). However, this estimation was not limited to
Emiratis and included burden of non-metabolic risk factors. In another recent
publication attempted to study the burden of cardiovascular risk factors in 33,000
young military men, it was estimated that 24% had at least 2 risk factors (37). This rate
is probably underestimated as the sample subjects were military men, which have
differences in age structure, social and behavioral characteristics.
This thesis investigated the associations between social and behavioral
determinants and the accumulation of 2 or more cardiometabolic risk factors for the
first time in the UAE. Aging had a consistent 10% increase in the odds of the
accumulation in both males and females. It is well known that aging increases the risk
for cardiovascular disease as there are multiple structural and functional alterations
that occur throughout a lifespan (168). For instance, changes at the molecular level,
such as the increase in oxidative stress can lead to obesity, diabetes, and frailty, which
is called “cardiovascular aging”. Having a lower educational accomplishment
increased the odds of accumulating cardiometabolic risk factors in the whole sample
by 37%, and in women by 61%. Degano et al. (169) reported that people with primary
or lower education had a 49% increase in the risk for CVD incidence. They also
reported that education affected CVD by affecting hypertension, BMI and diabetes.
Finally, having a family history of metabolic disease increased the odds up to 64%.
These findings show the need to develop preventive strategies and screenings targeted
for high-risk individuals with lower education and with family history of NCDs.
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6.3 Objective 3: Investigate the effect of BMI on the other cardiometabolic risk
factors and their burden.
The third phase of the project was designed to assess the burden of risk factors
by the different BMI classes. The aim was to describe for the first time in the country,
how each cardiometabolic risk factor and their accumulation might differ in people
with normal BMI, overweight, and obese. The age-adjusted prevalence rates were
substantially higher in the obese group compared to those of normal weight. For
instance, the proportion of those with abnormal HbA1c increased in the obese group,
3.3-folds in men and by 7-folds in women. Abnormal fasting glucose was also seen to
increase in the obese group, 1.6 folds in men and 4 folds in women. With regards to
lipid markers, the rates doubled in the obese group compared to the normal weight
group across both genders. The risk of hypertension was also elevated, 3.4 folds in
men and 6.5 folds in women. Lastly, central obesity had a 4-fold and 5-fold increase
in men and women, respectively.
Interestingly, the proportions with abnormal cardiometabolic markers were
higher in the normal BMI group in the youngest age group below 20 years old,
compared to the other BMI groups within the same age group. This was seen for
increased glycated hemoglobin, fasting glucose, lipid markers, and blood pressure.
This finding suggests that young people with normal weight are not protected from
having other metabolic abnormalities. This suggests that being young and of normal
BMI range does not necessarily indicate a metabolically healthy status. Moreover, the
results suggest that with increasing BMI, the number of risk factors accumulate. This
suggestion can be explained from the abdominal obesity perspective. For instance,
having central obesity but normal BMI was shown to have increased odds of
cardiovascular risk factors and accumulation (101). In another report, among 5000
individuals non-obese with normal-BMI, there was a significantly increased
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prevalence of high blood pressure, high fasting glucose, and dyslipidemia (170). Their
logistic regression analysis showed significantly increased odds in high blood pressure
(OR = 1.53; 95% CI = 1.20–1.94), low HDL cholesterol (OR = 2.06; 95% CI = 1.09–
3.89), and high trygliceride level (OR = 1.65; 95% CI = 1.27–2.16).
Although BMI does not differentiate between lean mass and fat mass (171), it
was highly correlated with body fat percentage in this study (correlation= 0.74), Figure
22.

Figure 22: Body fat percent and BMI agreement

6.4 Metabolic Syndrome
Although the thesis addressed the burden of cardiometabolic risk factors based
on predefined definitions, additional estimates of the rate of Metabolic Syndrome
(MetS) using the ATP3 criteria were performed. The ATP3 criteria for identifying
MetS is having 3 out of 5 metabolic abnormalities (172). The results are summarized
in Table 17.
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Table 17: Metabolic Syndrome in the sample.
Metabolic Syndrome using the ATP 3 definition.
Criteria: (3/5) of the following:
- Central obesity (Men > 102 cm, Women > 88 cm)
- Fasting Triglycerides (≥150 mg/dL) or taking lipid medication
- Fasting HDL cholesterol (Men <40 mg/dL, women <50 mg/dL) or taking
lipid medication
- Fasting glucose ≥110 mg/dL or taking antidiabetic medication
- Blood pressure ≥130/≥85 mm Hg or taking blood pressure lowering
medication
Results:
- Central obesity 1,015/4,819 (21.1%)
- High TG 189/1,127 (16.8%)
- Low HDL 449/1,129 (39.8%)
- High Blood Pressure 1,989/4,844 (41.1%)
- High glucose 117/1,108 (10.6%)
Metabolic Syndrome in the population (n=1,052) = 14.7%
Age-adjusted prevalence= 14.0% (11.8-16.1)

Crude Metabolic Syndrome
%
Age-adjusted %

Men (n=765)
16.2%

Women (n=287)
10.8%

15.8% (CI 13.218.4)

8.5% (CI 5.0-12.0)

Only few studies in UAE estimated metabolic syndrome. Two cross-sectional
studies in 2008 estimated the prevalence in UAE nationals aged 20 to over 60. The
rates estimated were 22.7% and 42.4% (40, 173). Another study on Emirati young
women aged 17-25 years estimated the prevalence to be 6.8% (38).
This thesis’s findings, along with the previously published results, show that
metabolic syndrome rates are higher in UAE’s young adults compared to the US young
adults aged 20-40. The NHANES 3 estimated the prevalence of metabolic syndrome
in this age group as 10.7%, their age-adjusted prevalence in the whole NHANES
cohort, across all ages up to over 60 was 25.2% (174).
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6.5 Strengths and Limitations
The principal strengths of this study include the large sample size of young
Emiratis, and the extensive information collected. This study mainly focused on
recruiting young adults, who are often underrepresented in other non-communicable
disease studies. The thorough process collected various data points, from
sociodemographic, to lifestyle behaviors, health and family history. All blood samples
and physical measurements were collected in a standardized procedure to ensure
consistent quality and reduce the risk of information bias. All of these data points
allowed to employ detailed and specific disease-identification criteria.
Most epidemiological studies have the risk of having selection bias that can
affect the external validity of the study. Selection bias is introduced at the
individual/group selection level, where proper randomization is not achieved and
therefore rendered unrepresentative of the population to be analyzed (175). The main
weakness of this study is that it is based on voluntary recruitment of participants. This
might introduce the risk of having selection bias and potentially affect the
representativeness of the study sample. Another weakness observed is that more males
(60%) were recruited than females (40%), and that they were recruited from different
centers. The analysis of the results therefore varied and described separately for each
gender. Moreover, it is essential to address a major limitation related to cross-sectional
studies, which is the inability to identify a causal relationship between the potential
risk factor and outcome. Therefore, the results of this study must be interpreted
cautiously and inferred to the local populations of similar age and sociodemographic
characteristics. Besides selection bias, that is attributable to the volunteer sample
recruitment, this study must take into consideration potential information bias and
confounding. Information bias is defined as any systematic difference from the truth
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that arise in the data collection steps (176). Similar to other observational studies, this
study is prone for measurements bias, recall bias and misclassification bias.
This study used a broad definition for dyslipidemia, which was based on 4 lipid
markers, self-report and the use of lipid-lowering medication. This definition was
recommended by the ATP 3 guidelines for persons above 20 years old (177). Random
non-fasting samples were used for the analysis, which is unconventional to normal
practice. Traditionally, blood collection for lipid testing purposes are required to be
fasting samples. However, recent reports show that random blood samples are
acceptable. Observational studies demonstrate that in comparison to fasting level,
measurements only altered minimally, by 8 mg/dL or-0.2 mmol/L, when compared to
fasting lipid levels (160, 161). So far, there is no hard-scientific evidence to why
fasting samples are better than random samples when evaluating lipid profile for
cardiovascular risk prediction. In fact, most studies now recommend non-fasting
samples as they are easier to collect during the day and represent the normal
postprandial state of individuals. Many countries are now changing their guidelines
towards a consensus on measuring lipid profiles for cardiovascular risk prediction in
the non-fasting state to simplify blood sampling for patients, laboratories, and
clinicians worldwide (178).
The GPAQ, a self-reported questionnaire designed to estimate physical
activity, has undergone validity programs that showed it is a valid and reliable tool,
but also adaptable to incorporate cultural differences. It had been translated to many
languages and therefore several validation studies were carried to show its validity and
reliability in different countries and language settings. In UAE, there were no GPAQ
validity studies yet. Researchers also use accelerometers and/or pedometers to collect
physical activity data, which is the gold standard method for physical activity data
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collection. Most studies conclude that GPAQ is an acceptable measure of physical
activity, and the results ranged between fair-to-moderate validity in multiple languages
(179, 180). There are no GPAQ validation studies performed in the UAE. One Saudi
study designed to measure GPAQ validity against accelerometers. It concluded that
GPAQ had a low agreement with the accelerometer but can be a reliable tool for
estimating moderate to vigorous physical activity (181). However, when assessing
sedentary behavior, GPAQ remains to poorly capture that information. Sedentary
behavior is not synonymous with physical inactivity. An individual can be physically
active and also having long hours of sedentary behavior (139). Therefore, it is
important to address sedentary behavior independently from physical activity. The
amount of missing data was also relatively high for some important measures like the
physical activity, which was 55%. This may have been the reason for the lack of
association between physical inactivity and metabolic outcomes.
Confounding, also called “mixing of effects”, refers to the exposure’s effect on
a specific outcome is mixed with other additional factor/ or set of factors that leads to
a distortion of the true relationship (182). Confounding factors can mask the true
association between an exposure and outcome, which in turns makes it difficult to find
a clear causal link. An important characteristic of a confounder is that it is related to
both the exposure and outcome, without being an intermediate factor in the pathway
from exposure to outcome. To deal with known confounders, is to adjust for them in a
multivariate model. In this study, the available confounder were adjusted for, as
mentioned in the methods section. Nevertheless, the lack of dietary data, which is
another important behavioral risk factor that is known to affect cardiometabolic health,
was also another limiting factor to the study. Overall, it is not possible to measure and
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report all confounders, therefore, there always be residual confounders; which are
factors that cannot be measured or are unknown.
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Chapter 7: Conclusion and Recommendations
This thorough research on cardiometabolic risk factors provided novel and rich
information about the cardiovascular risk in young adults of the United Arab Emirates,
which present the majority age demographic of the country. This study confirmed that
the prevalence of obesity, dysglycemia, dyslipidemia, hypertension and central obesity
are alarmingly high. The study introduced how social and behavioral characteristics
play a role in the cardiometabolic risk factors distribution and how these
cardiometabolic risk factors co-exist and interplay with one another. For the first time
in UAE, this thesis investigated the accumulation – or burden – of cardiometabolic
risk factor in young adults and how the accumulation is affected by other variables.
Moreover, it assessed the relationship of different BMI classes on the risk factors
distribution and clustering.
7.1 Recommendations
Addressing the alarming prevalence of cardiometabolic risk factors and their
accumulation from a young age calls for taking measures to control them.
Understanding that some social groups are more prone for having a metabolic
abnormality can help design specific prevention measures towards them. For instance,
this research found that employed men had higher rates of cardiometabolic risk factors,
as well as, employment increased the risk for having a higher burden. This finding can
inspire to design special screening and awareness campaigns as well as interventional
campaigns for men at the workplace.
Comorbidity analysis in this study showed that dyslipidemia is almost always
simultaneously co-exist with other cardiometabolic abnormalities. This sheds a light
on people that are diagnosed with dyslipidemia. Such patients must be additionally
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screened more often for other risk factors and must be made aware that they would be
more prone for having another metabolic abnormality.
Another alarming finding was that young adults below the age of 20 years have
already accumulated multiple risk factors. It was shown also that although the majority
of this age group had normal BMI, some had higher proportions of abnormal markers,
when compared with those that were overweight and obese. Proving that normalweight young adults are not immune to cardiovascular risk must be translated into
intense preventive and screening programs across universities and schools.
Finally, in line with personalized medicine, there will be a need for designing
personalized cardiovascular prevention strategies. Personalized management of CVD
is defined as the selection of the best treatment for an individual patient. Individualized
recommendations must consider all factors available at hand. It could include the
genetic and epigenetic predisposition, choosing individual-specific treatment course
for cardiometabolic abnormalities, as well as, surgery, lifestyle modifications and/or
combinations. Application of the personalized medicine principles can enhance the
quality of life for patients at high risk for CVD.
7.2 Further research
The findings of this study provide a platform for further research. Further
research of other sociodemographic and behavioral factors and how they can affect
cardiovascular health in this population is recommended. The differences between
rural and urban living settings is an understudied subject in terms of health in UAE.
Furthermore, novel socio-behavioral factors like sleep patterns and mental status and
how they can affect the epidemiology of cardiometabolic risk factors and eventually
non-communicable disease are being studied globally and should be studied in the
UAE. Studying how family history affected the distribution and odds of
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cardiometabolic risk factors can pave the pathway for genetic analysis and contribution
in disease advancement. It is important to quantify the effect of genetic predisposition
to cardiovascular disease, and essential to study the genetic – lifestyle interactions.
Finally, addressing the heavy burden of risk factors is only a first step to
understand how clustering will affect the incidence of cardiovascular disease.
Understanding how clustering manifests, and which cardiometabolic abnormality
precedes the other, will offer a novel way to design target-group-specific measures for
the prevention of NCD development. The UAE Healthy Future Study is designed as a
longitudinal study. Such design is necessary to quantify the risk of cardiometabolic
outcomes. Advancing in this direction will have the potential to develop and design
risk score calculators for cardiovascular risk prediction that is appropriate for this
population.
7.3 UAE actions towards NCDs
The UAE is responding to the alarming rates of metabolic abnormalities by
setting political commitment to NCDs from the top leadership in the country to
different governments and structures. Providing world-class healthcare is one of the
six pillars of the UAE National Agenda in line with Vision 2021. The pillar titled
“long and healthy lives” emphasizes the importance of prevention medicine in
reducing the risk of NCDs. This is reflected in a number of federal government
strategies to measure rates of disease and to develop health promotional programs,
including setting quantifiable methods to measure the country’s performance against
its targets for 2021. NCDs related measures includes number of deaths from
cardiovascular diseases and cancers per 100,000 and prevalence of diabetes. Other
measures include the prevalence of smoking any tobacco product. The National
Strategy for Prevention and Control of NCDs 2017-2021 was introduced by the
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Ministry of Health and Prevention in line with WHO EMRO regional action plan. The
strategy aims to promote the practice of healthy lifestyle for the UAE community and
provide comprehensive and integrated healthcare in innovative and sustainable ways
to ensure the prevention of diseases. The ministry of health has begun to implement
many of the activities as listed in the national NCD action plan (2017-2021) and UAE
national agenda for 2021 (183, 184). A National NCDs committee was established in
2017 and contains representatives from across government. Prominent progress is
made concerning policies for NCDs prevention and control, such as the recent tobacco
taxation (100%) and recent taxes implemented on soft drinks (50%) and power drinks
(100%). The UAE cabinet adopted a decision to expand the list of excise products to
include sweetened beverages, sugary drinks and electronic smoking devices, starting
January 1, 2020 (184). Additionally, there are several initiatives to increase physical
activity by the Sport Authority, including the “30X30 challenge” and other similar
initiatives to mainstream physical activity.
Recognizing the huge public health impact of NCDs and common risk factors,
the UAE government has shown remarkable commitment and leadership by investing
in preventive measures. Other initiatives include 2021 Healthy Children initiative,
Junior Chef Program, and Implementation and development of policies to improve
access to nutritious and healthy food.
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Appendices
Appendix 1: The UAE Healthy Future Study Questionnaire
Section 1: Demographic data
Q. No
D1

Stem
Gender

D2

Marital Status

D3A

Emirate / city of residence

D3B

Area of residence

D4A

How many houses do you own? (include farm house,
Island house, beach house, house in different Emirate,
house in different country)
Do you or your family own or rent the primary housing
that you live in?

D5

D7

D7A

Q. No
D7B

D7C

D8

D10

Including yourself, how many people are living together
in your primary household? (Include those who usually
live in the house such as students living away from home
during term) Do not include people working in
your household
How are the other people who live with you related to
you? (You can select more than one answer)

Stem
How many people are working in your primary
household? (Please include drivers, housemaids,
cooks, farmers, etc.)
How many rooms are there in your house (not including
kitchens and bathrooms)?
How many cars or vans are owned, or available for
use, by you or members of your household? (please
include company vehicles if available for private use)
What is the total monthly income received by your
HOUSEHOLD in AED?

Responses / Categorical Label
01 Male
02 Female
01 Single
02 Married
03 Divorced/ separated
04 Widow/Widower
01 Abu Dhabi
02 Al Ain
03 Dubai
04 Sharjah
05 Ajman
06 Um Al Quwain
07 07 Ras Al Khaima
08 Fujairah
Select one from
List of areas
NN None of above
UN Do not know
DA Prefer not to answer
Enter number OR
UN Do not know OR
DA Prefer not to answer
Select one from
- 01 Own outright (by you or someone
in your household)
- 02 Own with a mortgage
- 03 Rent
- 04 Live in accomadation rent free /
government granted housing
- NN None of the above
- DA Prefer not to answer
Enter number OR
UN Do not know OR DA Prefer not to
answer

Select from
01 Husband or wife
02 Son and/or daughter
(include step- children)
03 Brother and/or sister
04 Mother and/or father
05 Grandparent
06 Grandchild
07 Other related
08 Other unrelated
DA Prefer not to answer
Responses / Categorical Label
Enter number OR
UN Do not know OR
DA Prefer not to answer
Enter number OR
UN Do not know OR
DA Prefer not to answer
Enter number OR
UN Do not know OR
DA Prefer not to answer
Select one from
01 Less than 20,000
02 20,000 to 39,999
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D10A

How many times a year do you travel overseas for a
holiday?

D9

Which of the following describes your current situation?
(You can select more than one answer)

D9A1

Which of the following describes your occupation?

D9A

In a typical WEEK, how many hours do you spend at
work? (Do not include hours travelling to and from
work)
Stem
What level of activity is involved in your main
occupation?

Q. No
D9E

D9F

Does your work involve shift work?

D9DA

Does your job involve working during the night?

03 40,000 to 59,999
04 60,000 to 79,999
05 80,000 to 99,000
06 100,000 to 119,000
07 Greater than 120,000
UN Do not know
DA Prefer not to answer
Enter number OR
UN Do not know OR
DA Prefer not to answer
Select from
01 In paid employment,
02 Self-employed (e.g. consultant)
03 Business man / business women
04 Employer
05 Retired
06 House wife
07 Unable to work because of
sickness or disability
08 Unemployed
09 Doing unpaid or voluntary work
10 Full or part-time student
NN None of the above
DA Prefer not to answer
Select from:
01 Manager
02 Professional
03 Technician or Associate
professional
04 Clerical support worker
05 Service or sales worker
06 Agricultural, forestry or
fishery worker
07 Craft or related trades
08 Plant or machine operator
09 Elementary occupation
NN None of the above
DA Prefer not to answer
Enter number OR
UN Do not know OR
DA Prefer not to answer
Responses / Categorical Label
Select one from
01 Sitting most of the time
02 Standing most of the time
03 Walking most of the time
04 Sitting, standing, and
walking in equal amounts
05 Other work with moderate
physical activity (includes moving
or lifting objects of moderate
weight)
06 Physically heavy work (includes
moving or lifting heavy objects or
activities)
UN Do not know
DA Prefer not to answer
Select one from
01 Never/rarely
02 Sometimes
03 Usually
04 Always
UN Do not know
DA Prefer not to answer
Select one from
01 Never/rarely
02 Sometimes

113
D10

For how many years have you not been working?

D11

What is the highest level of education that you have
completed?

D12

How old were when you/your family first owned your
own house?

D12A

How old were you when your house first had an indoor
toilet?

Q. No
D12B

Stem
How old were you when your house first had Air
Conditioning?

D12C

How old were you when your household first had a car?

D12D

How old were you when your household first had a
housemaid /cook / driver/ gardener?

Q. No
D13
D13A

Stem
Where did you and your family live at around the time:
Of your birth

D13C

03 Usually
04 Always
UN Do not know
DA Prefer not to answer

When you were 18 years old

One or less
More than one year ago
Never worked before
Prefer not to answer
Select from
01 Did not attend or
complete primary school
02 Primary school
03 Middle school
03 Secondary school
04 University
05 Postgraduate degree (e.g Masters
or PhD)
NN None of the above
DA Prefer not to answer
Enter number OR
Select one from
01From birth.
02 We live in rented accommodation
UN Do not know
DA Prefer not to answer
Enter number OR
Select one from
01 From birth.
02 We don’t have an indoor toilet
UN Do not know
DA Prefer not to answer
Responses / Categorical Label
Enter number OR
Select one from
01 From birth.
02 We don’t have AC
UN Do not know
DA Prefer not to answer
Enter number OR
Select one from
01 From birth.
02 We don’t have a car
UN Do not know
DA Prefer not to answer
Enter number OR
Select one from
01 From birth.
02 We don’t have a housemaid/ cook/
driver
/ gardener
UN Do not know
DA Prefer not to answer
Responses
Select one from
01 City
02 Village
03 Desert (bedouin)
04 Island
05 Other
UN Do not know
DA Prefer not to answer
Select one from
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Now

Q. No
D14
D14A

D14C

Stem
In what type of housing did you live at around the time:
Of your birth

When you were 18 years old

Now

D15

In a typical week, on how many days is incense
burned in your home?

01 City
02 Village
03 Desert (bedouin)
04 Island
05 Other
UN Do not know
DA Prefer not to answer
Select one from
01 City
02 Village
03 Desert (bedouin)
04 Island
05 Other
UN Do not know
DA Prefer not to answer
Responses / Categorical Label
Select one from
01 Villa
02 Apartment
03 Shabiyah
04 Other
UN Do not know
DA Prefer not to answer
Select one from
01 Villa
02 Apartment
03 Shabiyah
04 Other
UN Do not know
DA Prefer not to answer
Select one from
01 Villa
02 Apartment
03 Shabiyah
04 Other
UN Do not know
DA Prefer not to answer
Never
One day per week or less
Frequently (2 -5 days per week)
Almost every day (6-7 days per
week)
UN Do not know
DA Prefer not to answer
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Section 2: Physical Activity, sleep and smoking
Physical Activity
Next I am going to ask you about the time you spend doing different types of physical activity in a typical
week. Please answer these questions even if you do not consider yourself to be a physically active person.
Think first about the time you spend doing work. Think of work as the things that you have to do such as paid
or unpaid work, study/training, household chores, harvesting food/crops, fishing or hunting for food, seeking
employment. [Insert other examples if needed]. In answering the following questions 'vigorous-intensity
activities' are activities that require hard physical effort and cause large increases in breathing or heart rate,
'moderate-intensity activities' are activities that require moderate
physical effort and cause small increases in breathing or heart rate.
Questions
Response
Activity at work
1

Does your work involve vigorous-intensity
activity that causes large increases in breathing Yes
or heart rate like [carrying or lifting heavy
loads, digging or construction work] for at
No
least 10 minutes continuously?
[INSERT EXAMPLES] (USE SHOWCARD)
2 In a typical week, on how many days do you do Number
vigorousof
intensity activities as part of your work?
days
3 How much time do you spend doing vigorous- Hours :
intensity
minutes
activities at work on a typical day?
4 Does your work involve moderateYes
intensity activity that causes small
increases in breathing or heart rate such as
brisk walking [or carrying light loads] for
No
at least 10 minutes continuously?
[INSERT EXAMPLES] (USE SHOWCARD)
5 In a typical week, on how many days do you Number of
do moderatedays
intensity activities as part of your work?
6 How much time do you spend doing
Hours :
moderate-intensity
minutes
activities at work on a typical day?
Travel to and from places

1
2

If No, go to P 4

└─┘
└─┴─┘:└─┴─┘
Hrs mins

1
2

If No, go to P 7

└─┘
└─┴─┘:└─┴─┘
hrs
mins

The next questions exclude the physical activities at work that you have already mentioned.
Now I would like to ask you about the usual way you travel to and from places. For example to work, for
shopping, to market, to place of worship. [insert other examples if needed]
7

Do you walk or use a bicycle (pedal
cycle) for at least 10 minutes continuously
to get to and from places?

8

In a typical week, on how many days do
you walk or bicycle for at least 10
minutes continuously to get to and
from places?
9 How much time do you spend walking or
bicycling for
travel on a typical day?
Recreational activities

Yes

1

No

2

Number
of days
Hours :
minutes

If No, go to P 10

└─┘
└─┴─┘:└─┴─┘
hrs
mins

The next questions exclude the work and transport activities that you have already mentioned.
Now I would like to ask you about sports, fitness and recreational activities (leisure), [insert relevant terms].
1 Do you do any vigorous-intensity sports,
0 fitness or recreational (leisure) activities that
cause large increases in breathing or heart
rate like [running or football,] for at least 10
minutes continuously?
[INSERT EXAMPLES] (USE SHOWCARD)

Yes

No

1
2

If No, go to P 13
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1 In a typical week, on how many days do
1 you do vigorous- intensity sports, fitness
or recreational (leisure) activities?
1 How much time do you spend doing
2 vigorous-intensity
sports, fitness or recreational activities on a
typical day?
Physical Activity (recreational activities) contd.
Questions
Do you do any moderate-intensity sports,
fitness or recreational (leisure) activities
that causes a small increase in breathing or
heart rate such as brisk walking,(cycling,
swimming, volleyball)for at least 10
minutes continuously?
[INSERT EXAMPLES] (USE SHOWCARD)
14
In a typical week, on how many
days do you do moderate-intensity
sports, fitness or recreational
(leisure) activities?
15
How much time do you spend doing
moderate-intensity sports, fitness or
recreational (leisure) activities on a typical
day?
Sedentary behaviour

Number
of days

└─┘

Hours :
minutes

└─┴─┘:└─┴─┘
hrs
mins

Response

13

Yes
1
2

If No, go to P16

No

Number of
days

Hours :
minutes

└─┘
└─┴─┘:└─┴─┘
hrs
mins

The following question is about sitting or reclining at work, at home, getting to and from places, or with friends
including time spent [sitting at a desk, sitting with friends, travelling in car, bus, train, reading, playing cards or
watching television], but do not include time spent sleeping.
[INSERT EXAMPLES] (USE SHOWCARD)
16

How much time do you usually spend sitting or
reclining on a typical day?

Hours :
minutes

└─┴─┘: └─┴─┘
hrs
min s

WP11

How often do you visit friends or family or have them
visit you?

Select one from
01 Almost daily
02 2-4 times a week
03 About once a week
04 About once a month
05 Once every few months
06 Never or almost never
07 No friends/family outside household
UN Do not know
DA Prefer not to answer

WP12

Which of the following do you attend once a week or
more often? (You can select more than one)

Select from
01 Sports club or gym
02 Mosque
03 Adult education class
04 Family development foundation
05 Other group activity
NN None of the above
DA Prefer not to answer

WP12A In a typical DAY in summer, how many hours do you
spend outdoors and are exposed to the sun?

Enter
number
OR
FR Less than an hour
a day OR
UN Do not
know OR
DA Prefer not to answer
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WP12B In a typical DAY in winter, how many hours do you
spend outdoors and are exposed to the sun?

WP5

In a typical DAY, how many hours do you spend
watching TV or using a computer, tablet,
smartphone(do not include using a computer at work;
put 0 if you do not spend any time doing it)?

WP7

In a typical DAY, how many hours do you spend
driving?

SL1

About how many hours sleep do you get in every 24
hours?
(please include naps)

Enter
number
OR
FR Less than an hour
a day OR
UN Do not
know OR
DA Prefer not to answer
Enter
number
OR
FR Less than an hour
a day OR
UN Do not
know OR
DA Prefer not to answer
Enter
number
OR
FR Less than an hour
a day OR
UN Do not
know OR
DA Prefer not to answer

Enter number
OR
UN Do not know
OR
DA Prefer not to answer
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SL1A

On an average day, how easy do you find getting up in
the morning?

Select one from
01 Not at all easy
02 Not very easy
03 Fairly easy
04 Very easy
UN Do not know
DA Prefer not to answer

SL1B

Do you have a nap during the day?

Select one from
01 Never/Rarely
02 Sometimes
03 Usually
DA Prefer not to answer

SL2

Do you have trouble falling asleep at night or do you
wake up in the middle of the night?

Select one from
01 Never/Rarely
02 Sometimes
03 Usually
DA Prefer not to answer

SL4

Do you snore loudly (louder than talking or loud
enough to be heard through closed doors)?

Select one from
01Yes
02 No
UN Do not know
DA Prefer not to answer

SL5

Do you often feel tired, fatigued or sleepy during
daytime?

Select one from
01Yes
02 No
UN Do not know
DA Prefer not to answer

SL6

Has anyone observed you stopping breathing during your
sleep?

Select one from
01Yes
02 No
UN Do not know
DA Prefer not to answer

Q. No

Stem

INTRO
4

Now, some questions about smoking and
tobacco use..
Press ‘next’ to continue.
FR87225 We will begin by asking you about
your use of cigarettes.
On average, how often do you
smoke cigarettes?
If response=5, 8
or 9, go to
FR87501. If
response=1-4, go
to BI87345.
FR87501
Have you ever smoked cigarettes, even one
time?

BI87345

Have you smoked 100 or more cigarettes
over your lifetime?
100 cigarettes= 5 packs of 20 cigarettes OR
4 packs of 25 cigarettes.

FR87216

On average, how many whole cigarettes
do you smoke per day? (1 pack typically
contains 20 cigarettes.)

Responses
Only one selection
- Next
1
2
3
4
5
8
9

Daily
Less than daily, but at least once a week
Less than weekly, but at least once a month
Less than monthly
Not at all
Refused
Don't know

1
2
8
9

Yes
No
Refused
Don't know

1
2
8
9

Yes
No
Refused
Don't know

Enter number of cigarettes.
88 Refused
99 Don't know
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FR87226

001 001
On average, how many whole cigarettes do 002 002
you smoke per
week? (1 pack typically contains 20 cigarettes.)

FR87201
During of the past 30 days, on how many days did
you smoke cigarettes?

003 003
…
100 100
101 More
than 100
888 Refused
999 Don't Know
Enter number of cigarettes.
(Program values of range 1 - 100 with
additional text response of 'More than 100'.)
Enter number of days. (Range 00-30)
88 Refused
99 Don't know

FR87202

On average, on days that you smoked cigarettes,
Enter number of cigarettes or choose one of
about how many cigarettes did you smoke per day? the coded responses.
88 Refused
(1 pack typically contains 20 cigarettes.)
99 Don't know

FR87118

How old were you when you first tried cigarette
smoking, even one or two puffs?

88 Refused
99 Don't know

FR87510 Ask if (FR87225=2-4) or (FR87501=1).
(Prev.
At the time when you were smoking cigarettes
most often, how often did you smoke them?
NW875
00)

1 Daily or almost daily; most days
2 Less than daily, but at least once a
week
3 Less than weekly, but at least
once a month
4 Less than monthly
5 Not at all
8 Refused
9 Don't know

FR87116 Ask if FR87510=1 or FR87225=1.
(Prev.
How old were you when you first started smoking
NW875
cigarettes on most days?
01)

88 Refused
99 Don't know
(Range 1 - 87)

FR87131 Ask if FR87510=1.
During the time when you smoked cigarettes most
(Prev.
NW875
days, on average, how many cigarettes did you
02)
smoke each day?

001 001
002 002
003 003
…
100 100
101 More than 100
88 Refused
99 Don't know
Enter number of cigarettes.
(Program values of range 1 - 100 with
additional text
response of 'More than 100'.)
FR87127 Ask if FR87510=1.
88 Refused
(Prev.
How old were you when you last smoked cigarettes
99 Don't know
(Range 1 - 87)
NW875
on most days?
03)
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MK8722 Ask all.
6
We are now going to ask you about your use of
midwakh/dokha.
On average, how often do you smoke
midwakh/dokha?

1 Daily
2 Less than daily, but at least once a
week
3 Less than weekly, but at least
once a month
4 Less than monthly
5 Not at all
8 Refused
9 Don't know

MK8750
1

1 Yes
2 No

Have you ever smoked midwakh/dokha, even one
time?

8 Refused
9 Don't know
MK8720
1

MK8721
7

MK8721
6

MK8724
1

How many times have you smoked midwakh/dokha
in your entire life?

On average, how many times do you smoke
midwakh/dokha each day?

On average, how many times do you smoke
midwakh/dokha each week?

88 Refused
99 Don't know

During the past 30 days, on how many days did you
smoke midwakh/dokha?

88 Refused
99 Don't know
Enter number of days. (Range 00-30)

MK8724 Ask if MK87241=1-30.
2
On average, on days that you smoked
midwakh/dokha, about how many times did you
smoke it per day?
MK8751
8

1 Two or fewer
2 3-10
times 3
11-20
times 4
21-50
times 5
51-99
times
6 100 or more
8 Refused
9 Don't know
88 Refused
99 Don't know

How old were you when you first tried smoking
midwakh/dokha, even one or two puffs?

MK8753 Ask if (FR87225=2-4) or (FR87501=1).
At the time when you were smoking
5 (Prev.
midwakh/dokha most often, how often did you
NW875
05)
smoke them?

88 Refused
99 Don't know

88 Refused
99 Don't know

1 Daily or almost daily; most days
2 Less than daily, but at least once a week
3 Less than weekly, but at least once a
month
4 Less than monthly
5 Not at all
8 Refused
9 Don't know

121
MK8751 Ask if FR87510=1 or FR87225=1.
9 (Prev.
How old were you when you first started smoking
midwakh/dokha on most days?
NW875
06)

88 Refused
99 Don't know
(Range 1 - 87)

MK8753 Ask if FR87510=1.
During the time when you smoked midwakh/dokha
0 (Prev.
most days, on average, how many cigarettes did you
NW875
smoke each day?
07)

001 001
002 002
003 003
…
100 100
101 More than 100
88 Refused
99 Don't know
Enter number of cigarettes.
(Program values of range 1 - 100 with
additional text response of 'More than 100'.)

MK8753 Ask if FR87510=1.
How old were you when you last smoked
2 (Prev.
midwakh/dokha on

88 Refused
99 Don't know

NW875
08)

(Range 1 - 87)

most days?

HK8720 Ask all.
9
We are now going to ask you about your use of shisha
(also known as waterpipe, hookah, narghile).
Do you smoke shisha…?

1
2
3
4
8
9

HK8722 Ask if HK87209=1, 2 or 3.
6
On average, how often do you smoke shisha (on
your own or in a shared session with others)?

1 Daily or almost daily; most days
2 Less than daily, but at least once a
week
3 Less than weekly, but at least once
a month
4 Less than monthly
5 Not at all
8 Refused
9 Don't know

NC8780
2

Have you ever smoked shisha, even one time?

1
2
8
9

NC8780
7

How many times have you smoked shisha in your
entire life?

HK8721
7

On average, how many times per day do you
smoke shisha?

Mainly on your own
Mainly shared with others
Alone and shared, about equally
Not at all
Refused
Don't know

Yes
No
Refused
Don't know

Two or fewer
2
310 times 3
11-20 times 4
21-50 times 5
51-99 times
6 100 or more
Refused
Don't know
88 Refused
99 Don't know
(Range 1 - 50)
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HK8721
6

On average, how many times per week do you
smoke shisha?

001 001
002 002
003 003
…
100 100
101 More
than 100 888
Refused
999 Don't Know
(Program values of range 1 - 100 with
additional text response of 'More than 100'.)

NC8782
2

During the past 30 days, on how many days did
you smoke shisha?

88 Refused
99 Don't know
Enter number of days. (Range 00-30)

NC8782
3

On average, on days that you smoked shisha, about
how many times per day did you do that?

88 Refused
99 Don't know
(Range 1 - 50)

HK8726
6

On average, each time you smoke shisha, how
many shisha heads do you smoke?

88 Refused
99 Don't know
(Range 1 - 50)

HK8726

How many shisha heads per week do you usually
smoke?

001 001

8

HK8774
4

On average, of those times you smoke shisha, how
often does your shisha contain tobacco?

HK8773
2

Where do you most often smoke shisha?

1
2
3
4
5

1
2
3
4
5

002 002
003 003
…
100 100
101 More than
100 888 Refused
999 Don't Know
(Program values of range 1 - 100 with
additional text response of 'More than
100'.)
Never
Less than half the time
Half the time
More than half the time, but not always
Always
8 Refused
9 Don't know
At home
Coffee shop
Bar/ club
Restaurant
Other, specify
8 Refused
9 Don't know

HK8773
2o

Specify other location:

88 Refused
99 Don't know

NC8781
0

How old were you when you first tried smoking
ANY shisha (includes any shisha that was smoked
on your own or shared), even one or two puffs?

88 Refused
99 Don't know
(Range 1 - 87)
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HK8753
5 (Prev.
NW875
11)

At the time when you were smoking shisha most
often, how often did you smoke it?

1 Daily or almost daily; most days
2 Less than daily, but at least once a week
3 Less than weekly, but at least once a
month
4 Less than monthly
5 Not at all
8 Refused
9 Don't know

HK8751
How old were you when you first started smoking
shisha on most days?
9 (Prev.
NW875
12)
HK8753
During the time when you smoked shisha on most
days, on average, how many times a day did you
0 (Prev.
smoke it?
NW875
13)
HK8753
How old were you when you last smoked shisha on
most days?
2 (Prev.
NW875
14)
ET87091 Ask all.
Thinking about INSIDE YOUR HOME… Over
the last 7 days, for how many hours were you
exposed to other people’s TOBACCO smoke,
including smoke from cigarettes, midwakh, or
shisha?

88 Refused
99 Don't know
(Range 1 - 87)

ET87092 Ask all.
Thinking about INDOOR PUBLIC PLACES… Over
the last 7 days, for how many hours were you exposed
to other people’s TOBACCO smoke, including smoke
from cigarettes, midwakh, or shisha? (e.g. in school,
shops, restaurants, shopping malls,
movie theaters.)

Enter number
88 Refused
99 Don't know

88 Refused
99 Don't know
(Range 1 - 50)
88 Refused
99 Don't know
(Range 1 - 87)
Enter number
88 Refused
99 Don't know
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ET87093 Ask all.
Thinking about OUTDOOR PUBLIC PLACES…
Over the last 7 days, for how many hours were you
exposed to other people’s TOBACCO smoke,
including smoke from cigarettes, midwakh, or
shisha? (e.g. at playgrounds, sidewalks, entrances
to buildings, parks, beaches.)

Enter number
88 Refused
99 Don't know

SL87210 Ask all.
Do you use any tobacco that is not smoked?

1 Yes, chewing tobacco
2 Yes, Naswar
3 Yes, other
4 No
8 Refused
9 Don't know

Section 3: Family history and early exposures
Q. No
INTRO
5
Y1

Stem
Now, some questions about you and your family.
Press ‘next’ to continue.
In which country were you born?

Responses

Y2

What year did you first come to live in the United
Arab Emirates?

Y2A

What was your birth weight (in kg)?

Y3

Were you breastfed when you were a baby?

Enter
number
OR
UN Do not
know OR
DA Prefer not to answer
Weight in
kilograms
999 Do not
know
888 Prefer not to answer
Select one from
01 Yes
00 No
UN Do not know
DA Prefer not to answer

Y3A

How many months were you breastfed when you
were a baby?

Y4

When you were 10 years old, compared to average
would you describe yourself as:

Only one selection
- Next
Select one from
1. United Arab Emirates
2. Other
UN Do not know
DA Prefer not to answer

Enter
number
OR
UN Do not
know OR
DA Prefer not to answer
Select one from
01 Thinner
02 Plumper
03 About average
UN Do not know
DA Prefer not to answer
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Y5

When you were 10 years old, compared to average
would you describe yourself as:

Select one from
01 Shorter
02 Taller
03 About average
UN Do not know
DA Prefer not to answer

Y6

Approximately how much did you weigh (in
Kilograms) when you were 18 years old?

Q. No
Y7

Stem
Did your mother smoke regularly around the time
when you were born?

Weight in kilograms
Do not know
Prefer not to answer
Responses
Select one from
YE Yes
NO No
UN Do not know
DA Prefer not to answer

Y8

Did your father smoke regularly around the time
when you were born?

Select one from
YE Yes
NO No
UN Do not know
DA Prefer not to answer

Y13D

Does/did your father ever suffer from? (You can
select more than one answer)

Select from
HE Heart disease
ST Stroke
BP High blood pressure
DB Diabetes
OB Obesity
CH High cholesterol
NN None of the above
UN Do not know
DA Prefer not to answer

Y16D

Has/did your mother ever suffer from? (You can
select more than one answer)

Y18

How many siblings do you have? (Please include
those who have died. Do not include half-sisters,
step-sisters or adopted sisters)

Y19

Have any of your brothers or sisters suffered from
any of the following illnesses? (You can select more
than one answer)

Y23

Before their marriage, what was the family
relationship between your father and your mother?

Select from
HE Heart disease
ST Stroke
BP High blood pressure
DB Diabetes
OB Obesity
CH High cholesterol NN None of the
above
UN Do not know
DA Prefer not to answer
Enter
number
OR
UN Do not
know OR
DA Prefer not to answer
Select from
HE Heart disease
ST Stroke
BP High blood pressure
DB Diabetes
OB Obesity
CH High cholesterol NN None of the
above
UN Do not know
DA Prefer not to answer
Selec
t
from
00
None
01 First cousin
02 Second cousin
03 Less than second
cousin UN Do not
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know
DA Prefer not to answer

How old were you when you got married?

Y24

-

Age
Do not remember
Prefer not to answer

Section 4: Psychological health
Q. No
INTRO
5
Y1

Stem
Now, some questions about you and your family.
Press ‘next’ to continue.
In which country were you born?

Q. No

Stem

Y2

What year did you first come to live in the United
Arab Emirates?

Y2A

What was your birth weight (in kg)?

Y3

Were you breastfed when you were a baby?

Y3A

How many months were you breastfed when you
were a baby?

Y4

When you were 10 years old, compared to average
would you describe yourself as:

Y5

When you were 10 years old, compared to average
would you describe yourself as:

Y6

Approximately how much did you weigh (in
Kilograms) when you were 18 years old?

Responses
Only one selection
- Next
Select one from
3. United Arab Emirates
Responses
4. Other
UN Do not know
DA Prefer not to answer
Enter
number
OR
UN Do not
know OR
DA Prefer not to answer
Weight in
kilograms
999 Do not
know
888 Prefer not to answer
Select one from
01 Yes
00 No
UN Do not know
DA Prefer not to answer
Enter
number
OR
UN Do not
know OR
DA Prefer not to answer
Select one from
01 Thinner
02 Plumper
03 About average
UN Do not know
DA Prefer not to answer
Select one from
01 Shorter
02 Taller
03 About average
UN Do not know
DA Prefer not to answer
-

Weight in kilograms
Do not know
Prefer not to answer
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Y7

Did your mother smoke regularly around the time
when you were born?

Select one from
YE Yes
NO No
UN Do not know
DA Prefer not to answer

Y8

Did your father smoke regularly around the time
when you were born?

Select one from
YE Yes
NO No
UN Do not know
DA Prefer not to answer

Y13D

Does/did your father ever suffer from? (You can
select more than one answer)

Select from
HE Heart disease
ST Stroke
BP High blood pressure
DB Diabetes
OB Obesity
CH High cholesterol
NN None of the above
UN Do not know
DA Prefer not to answer

Q. No
Y16D

Stem
Has/did your mother ever suffer from? (You can
select more than one answer)

Y18

Y19

Y23

Y24

Responses
Select from
HE Heart disease
ST Stroke
BP High blood pressure
DB Diabetes
OB Obesity
CH High cholesterol NN None of the
above
UN Do not know
DA Prefer not to answer
How many siblings do you have? (Please include
Enter
those who have died. Do not include half-sisters,
number
step-sisters or adopted sisters)
OR
UN Do not
know OR
DA Prefer not to answer
Have any of your brothers or sisters suffered from
Select from
any of the following illnesses? (You can select more HE Heart disease
than one answer)
ST Stroke
BP High blood pressure
DB Diabetes
OB Obesity
CH High cholesterol NN None of the
above
UN Do not know
DA Prefer not to answer
Before their marriage, what was the family
Select
relationship between your father and your
from
mother?
00
None
01 First cousin
02 Second cousin
03 Less than second
cousin UN Do not
know
DA Prefer not to answer
How old were you when you got married?
Age
Do not remember
Prefer not to answer
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Section 5: General health

Q. No
INTRO8

Stem
Now some questions about your health. Please Press
‘next’ to
continue.
In general how would you rate your overall health
now ?

Responses
Only one selection
- Next

H1A

In general, how was your health in childhood (less
than 10 years old)?

Select one from
01 Excellent
02 Good
03 Fair
04 Poor
UN Do not know
DA Prefer not to answer

H2

Do you have any of the following?
(You can select more than one answer)

Select from
01 Mouth ulcers
02 Painful gums
03 Bleeding gums
04 Loose teeth
05 Toothache
06 Dentures
NN None of the above
DA Prefer not to answer

H2A

How many permanent teeth (other than wisdom
teeth) have you lost?

Enter number

H1

Select one from
01 Excellent
02 Good
03 Fair
04 Poor
UN Do not know
DA Prefer not to answer

UN Do not know
DA Prefer not to answer
Select from
YE Yes
NO No
UN Do not know
DA Prefer not to answer

H2C

Has your dentist told you that you have periodontal
disease?

H2D

How often do you use dental floss?

Select from
- Once daily
- Twice daily
- Three times daily or more
- Two to four times in a week
- Once a week or less
- Never
- Do not remember
- Prefer not to answer

H2E

How often do you brush your teeth?

Select from
- Once daily
- Twice daily
- Three times daily or more
- Two to four times in a week
- Once a week or less
- Never
- Do not remember
- Prefer not to answer

Q. No

Stem

Responses
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Questions for women only:
Has a doctor ever told you that you have polycystic
ovarian syndrome / disease?

Select from
YE Yes
NO No
UN Do not know
DA Prefer not to answer

How old were you when the doctor first told you
Enter
that you had polycystic ovarian syndrome / disease? number
OR
UN Do not
know OR
DA Prefer not to answer
Are you being treated for polycystic ovarian
Select from
syndrome / disease?
YE Yes
NO No
UN Do not know
DA Prefer not to answer
Q. No
L1

Stem
Has a doctor ever told you that you have had any
of the following conditions? (You can select more
than one answer)

Responses
Select from
04 Obesity
08 Asthma
09 Hayfever, allergic rhinitis or eczema
NN None of the above
DA Prefer not to answer

L1A

What was your age when the **** was first
diagnosed?

Enter
number
OR
UN Do not
know OR
DA Prefer not to answer
Select one from
YE Yes
NO No
UN Do not know
DA Prefer not to answer

“****” insert each condition from L1 if selected

L3

Has a doctor ever told you that you have diabetes?

L3A

Did you only have diabetes during pregnancy?

Select one from
YE Yes
NO No
NA Not applicable
UN Do not know
DA Prefer not to answer

L3B

What was your age when the diabetes was first
diagnosed?

L3C

Did you start insulin within one year of your
diagnosis of diabetes?

Enter
number
OR
UN Do not
know OR
DA Prefer not to answer
Select one from
YE Yes
NO No
UN Do not know
DA Prefer not to answer

L5

Has a doctor ever told you that you have or had high Select one from
cholesterol
YE Yes
NO No
UN Do not know
DA Prefer not to answer

L5A

How old were you when the doctor first told you
that you had high cholesterol?

-

Age
UN Do not remember
DA Prefer not to answer
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-

L5B

Are you being treated for high cholesterol?

L6

Has a doctor ever told you that you have or had high Select one from
blood pressure?
YE Yes
NO No
UN Do not know
DA Prefer not to answer

L6A

How old were you when the doctor first told you
that you had high blood pressure?

-

Age
UN Do not remember
DA Prefer not to answer

L6B

Are you being treated for high blood pressure?

-

01 Diet only
02 Tablets only
03 Diet and tablets
NO No
DA Prefer not to answer

Q. No
L8

Stem
Do you regularly take any of the following? (You
can select more than one answer)

Responses
Select from:
01 Aspirin
03 Paracetamol
NN None of the above
UN Do not know
DA Prefer not to answer

L9

Do you regularly take any PRESCRIPTION
medications? (Do not forget medications such as
puffers or patches)

Select one from
YE Yes – you will be asked about this
later by an interviewer
NO No
UN Do not know
DA Prefer not to answer

L10

Do you regularly take any of the following? (You
can select more than one answer)

Select from
04 Vitamin D
)
07 Multivitamins +/- minerals
NN None of the above
DA Prefer not to answer

L10A

Do you regularly take any of the following? (You
can select more than one answer)

Select from
01 Fish oil (including cod liver oil)
05 Iron
NN None of the above
DA Prefer not to answer

L11

How often have you taken a course of antibiotics
in the last year?

-

01 Never
02 Once
03 Twice
04 Three times
05 Four times or more
UN Do not remember
DA Prefer not to answer

L11A

Were the antibiotics taken in the last month?

-

01 Yes
02 No
UN Do not remember
DA Prefer not to answer

L12

Have you ever had bariatric surgery for weight loss? Select from
YE Yes
NO No
UN Do not know
DA Prefer not to answer

Diet only
Tablets only
Diet and tablets
No
Prefer not to answer
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L12A

How old were you when you had the surgery?

Has a doctor ever told you that you have
Thalassemia?

Has a doctor ever told you that you have
Thalassemia trait?

Is this?

Enter
number
OR
UN Do not
know OR
DA Prefer not to answer
Select from
YE Yes
NO No
UN Do not
know DA Prefer
not to answer
Select from
YE Yes
NO No
UN Do not
know DA Prefer
not to answer
Select from
α-thalassemia
β-thalassemia
UN Do not know
DA Prefer not to answer
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Appendix 2: Summary of prevalence rates for cardiometabolic risk factors.
Prevalence rates: UAEHFS 2016 - 2018: WHOLE
POPULATION
Crude
Age-adjusted
Age-standardized
Obesity
27.2 (25.9 – 28.4) 26.5 (25.2 – 27.7)
30.2 (28.9 - 31.7)
Diabetes
3.9 (3.4 - 4.4)
3.5 (3.0 – 4.0)
4.5 (3.9 - 5.2)
Prediabetes
8.7 (8.0 - 9.5)
8.2 (7.4 – 8.9)
10.1 (9.2 - 11.0)
Abnormal LDL
35.4 (34.1 - 36.7) 34.5 (33.2 – 35.9)
40.4 (38.9 - 41.8)
Abnormal HDL
43.8 (42.5 - 45.2) 43.7 (42.4 – 45.1)
46.7 (45.3 - 48.2)
Abnormal cholesterol
33.9 (32.6 - 35.2) 32.8 (31.4 – 34.1)
39.1 (37.7 - 40.5)
Abnormal Triglycerides 23.1 (21.9 - 24.3) 21.4 (20.2 – 22.6)
27.6 (26.2 - 28.9)
Hypertension
22.9 (21.7 – 24.1) 22.4 (21.2 – 23.6)
25.0 (23.7 - 26.4)
Central obesity
24.3 (23.1 – 25.5) 22.5 (21.3 – 23.8)
29.0 (27.6 - 30.4)
Prevalence rates: UAEHFS 2016 - 2018: MEN
Crude
Age-adjusted
Age-standardized
Obesity
30.1 (28.5 - 31.8) 29.7 (28 – 31.4)
32.0 (30.3 - 33.8)
Diabetes
4.0 (3.4 - 4.7)
3.8 (3.1 – 4.5)
4.4 (3.7 - 5.3)
Prediabetes
10.1 (9.1 – 11.2)
10.6 (9.5 - 11.7)
11.6 (10.5 - 12.9)
Abnormal LDL
42.5 (40.8 - 44.2) 42.1 (40.3 – 43.9)
46.0 (44.2 - 47.8)
Abnormal HDL
45.5 (43.7 - 47.2) 45.4 (43.6 – 47.1)
47.9 (46.1 - 49.8)
Abnormal cholesterol
38.0 (36.4 - 39.7) 37.2 (35.4 – 38.9)
41.8 (40.1 - 43.6)
Abnormal Triglycerides 28.2 (26.6 - 29.8) 26.7 (25.1 – 28.3)
31.9 (30.2 - 33.6)
Hypertension
31.0 (29.4 - 32.7) 30.9 (29.2 – 32.6)
32.1 (30.4 - 33.9)
Central obesity
30.9 (29.3 - 32.6) 29.6 (27.9 – 31.3)
34.8 (33 - 36.6)
Prevalence rates: UAEHFS 2016 - 2018: WOMEN
Crude
Age-adjusted
Age-standardized
Obesity
22.6 (20.8 - 24.6) 21.6 (19.7 – 23.5)
27.4 (25.1 - 29.8)
Diabetes
3.6 (2.9 - 4.5)
3.1 (2.3 – 3.9)
4.7 (3.7 - 6.1)
Prediabetes
5.6 (4.7 - 6.8)
5.2 (4.1 – 6.2)
6.9 (5.7 - 8.4)
Abnormal LDL
23.9 (22.0 - 25.8) 22.9 (20.9 – 24.8)
28.8 (26.5 - 31.3)
Abnormal HDL
41.2 (39.0 - 43.4) 41.1 (38.9 – 43.3)
44.1 (45.6 - 46.7)
Abnormal cholesterol
27.0 (25.1 - 29.1) 26.0 (24.0 – 28)
33.0 (30.6 - 35.5)
Abnormal Triglycerides 14.8 (13.3 - 16.4) 13.5 (11.9 – 15.1)
18.9 (16.9 - 21.2)
Hypertension
9.9 (8.7 - 11.4)
9.2 (7.8 – 10.5)
12.1 (10.5 - 14.0)
Central obesity
13.9 (12.4 - 15.5) 12.5 (10.9 – 14.0)
17.9 (15.9 - 20.1)
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